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ABSTRACT

This dissertation is in an integrated format discussing three major projects centered
around probe development. In the first project, novel metal-chelated and fluorinated GLP-1
derivatives were prepared all containing D-Ala-8, a modification known to improve
resistance towards degradation by dipeptidyl-peptidase IV. The effect of increased distance
between DOTA and the peptide chain was investigated using a spacer, in order to reduce
steric effects imposed by DOTA. Placement of linker and DOTA moieties were varied within
the GLP-1 sequence to test for optimal metal-complex location. Binding affinity of peptide
derivatives was determined in vitro with CHO/GLP-1R cell line and shown to be in the nM
range. In vivo imaging was carried out using C57BL/6 mice. Modifications made to the
peptide backbone, based on charge distribution, were shown to improve pharmacokinetics.
Our results suggest developed GLP-1 tracers to be potential candidates for the non-invasive
imaging of pancreatic islets in vivo.
In the second project, Gallium-chelated protoporphyrin IX (PPIX) derivatives
containing the tripeptide RGD αvβ3-targeting moiety were prepared and evaluated. Reaction
conditions for both naturally occurring 69/71Ga-labeling as well as 68Ga-radiolabeling were
optimized using a microwave reactor. Optical properties were evaluated in order to study the
effects of ligand conjugation and gallium chelation on absorption/emission properties of
PPIX. Quantum yields pre- and post gallium chelation were comparable, indicating that the
presence of gallium does not quench the inherent fluorescence of PPIX. The targeted
compound was preferentially taken up by αvβ3 integrin-expressing cancer cells versus the
non-targeted form, as assessed by fluorescence microscopy. Our results suggest that gallium-
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PPIX conjugates could be used as dual modality positron emission tomography/fluorescence
microscopy probes and can assist in bridging imaging agent discovery from in vitro
microscopy through to in vivo imaging.
In the third and final project, a novel high-throughput cell-based technique was
developed for screening one-bead-one-compound (OBOC) libraries. In order to validate this
technique, a small library consisting of heptameric peptides, and the αvβ3 integrins targeting
RGD sequence, was synthesized on Tentagel beads via a photo-labile linker. Compounds
were screened against the αvβ3-expressing MD 435 cell line. After fluorescent-based sorting,
peptides were photolytically cleaved off resin and analyzed using MALDI-TOF/TOF.
Deconvolution of all peptide sequences was carried out successfully indicating this screening
process to be a facile and efficient technique for discovery of novel targeting entities.

Keywords:

Radiochemistry, Gallium-68, Indium-111, Fluorine-18, PPIX, GLP-1, OBOC
library, molecular imaging
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CHAPTER 1. Molecular Imaging
1.1

Introduction
Over the past few decades, utilization of various imaging techniques has helped

shape our understanding of numerous biological processes. Advances in the development
of such techniques for small animals as well as human use, has increased the applications
of imaging to include biomedical research, such as those in drug development and
discovery. Historically, biomedical imaging methodologies relied on detection of disease
processes or treatment effects as anatomical abnormalities and were therefore referred to
as structural or conventional imaging. With the development of higher resolution
instrumentation and discovery of improved imaging agents, it became possible to
visualize physiological parameters in living subjects. This technique is commonly
classified as functional imaging. More recently, however, it has become possible to
image specific molecules and targets, which is a research discipline now referred to as
molecular imaging.1,
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This research area provides a method for the non-invasive

visualization, characterization and quantification of biological processes at cellular and
sub-cellular levels. Furthermore, molecular imaging has also been shown to play a vital
role in modern medicine as a result of its potential application in diagnostics and
therapeutics.3-6 Currently, two of the most important clinical applications of molecular
imaging are in oncology and cardiac disease imaging. In oncology, significant
breakthroughs have been achieved for treatment response assessment, cancer staging and
early disease detection.7-10 In the case of cardiovascular disease, imaging techniques have
provided a route for plaque detection as well as analysis of cardiac repair.11,

12

applications were made possible largely due to the development of imaging probes.

These

2
1.2

Imaging Probes
The non-invasive visualization of biological processes in vivo requires the use of

appropriately designed imaging probes. There are three main categories of imaging
probes namely: non-specific, targeted and activatable (Figure 1.1). Non-specific probes,
instead of interacting with specific molecular targets, accentuate differences between
tissues in terms of permeability and perfusion levels. These probes are typically utilized
in monitoring disease processes, which involve characterization of blood volume, flow or
perfusion. Non-specific probes are commonly utilized in imaging practices. A recent
example is a report on tumor drug delivery by non-covalently linked drug-gold
nanoparticle. In this study the gold-nanoparticles, acting as non-specific probes, travel to
the tumor site via enhanced permeability and retention (EPR) effect owing to the
presence of leaky vasculature as demonstrated in Figure 1.2.2, 13-17

Figure 1.1 Representative classes of imaging probes and their respective interaction
schemes.14, 17

3

Figure 1.2 A scheme demonstrating the localization of gold nanoparticles in tumors cells
via enhanced diffusion through leaky vasculature.13

Visualization and monitoring of disease processes requires targeting of specific
biological processes at cellular or sub-cellular levels. This requirement has led to the
development of targeted and activatable imaging probes. In principle, targeted probes get
localized on biomolecules of interest, thus allowing for the visualization of their
distribution.14 The mechanism of target-specific uptake is directly related to the
biochemical processes involved since site directed probes could include enzyme
substrates, inhibitors, transport protein ligands, membrane bound or cytosolic binding
sites as well as mRNA or DNA components.18 Targeted probes are detectable at all times,
regardless of any interaction with the biological target, which leads to higher background

4
noise levels. However, considering that only the probes bound to the biological targets
stay in the system, higher signal to noise ratios can be obtained if waiting periods are
permitted prior to imaging. Targeted probes are utilized in several areas of oncology
including heart, brain and tumor imaging as well as tumor therapy. Examples of such
probes and their applications are given in Table 1.1.

Probe
FMISO

Carazolol

Raclopride

Structure

Application
Hypoxic marker
heart

for

α-Adrenergic receptor
ligand
(myocardial
receptor present in many
heart disease)
D2-dopamine receptor
antagonist
(dopamine
activity in brain)

Octreotide
(Sandostatin®)

Study somatostatin
receptors found in a
number of human
tumors (eg. gastrinoma,
insulinoma, carcinoid,
neuroblastoma)

FLT

Monitoring
proliferation
lymphoma)

Table 1.1 Examples of targeted compounds for oncologic applications.19-24

tumor
(eg.

5
Activatable probes (also referred to as smart probes), do not produce a signal in
their native state and, considering that their detection requires interaction with their
intended biological targets, typically produce higher signal to noise ratios. Smart probes
can be activated by ionic interactions or enzymatic cleavage, and thus can also be used to
monitor the localization of molecular functions. Figure 1.3 illustrates the use of
activatable probes compared to other categories of molecular probes. A recently reported
class of smart probes includes the pH-activatable fluorescent probes used in molecular
imaging of viable cancer cells.14,

25

Pharmacokinetics of such probes, however, is not

ideal in all cases, as interference from other biological entities (eg. enzymes) is likely to
occur. Therefore, the choice of targeted versus smart probe is case dependent.

Figure 1.3 Scheme of targeted imaging probes (a) versus activatable “smart” probes (b).

6
1.3 Design of molecular imaging probes
The design of a molecular imaging probe requires special attention to a number of
key factors, the most important of which are 1) identification of a suitable biological
molecular target, 2) identification of a targeting entity with optimal affinity for the target
of interest, 3) labeling of the targeting entity with a suitable signaling molecule, thus the
modality, 4) overcoming the barriers in the biological delivery of the designed probe, and
5) if possible, finding ways to amplify the observed probe signal.14 Figure 1.4 illustrates
the general design of a targeted molecular imaging probe.14

Figure 1.4 Components of an imaging probe and its interaction with a biological target.

Finding the appropriate targeting ligand requires a screening process. Such
techniques are currently employed in the drug development industry and include phage
display, proteomics, robotics, recombinant techniques, and high throughput screening
methods, which have only recently been widely employed to identify molecular imaging
targets. Examples of potential molecular targets include nucleic acid sequences, proteins,
carbohydrates and lipids (Figure 1.5). The design of imaging probes requires several
considerations, which include: probe localization on the cell surface or within the cell,
quantity of biological target per cell, and probable steric issues that may hinder probe
delivery.14, 17

7

Figure 1.5 General outline of a cell showing commonly targeted entities.

The next step in the design of an imaging probe, once a biological target has been
selected, is the identification of a molecule that would specifically bind the target with
optimal affinity. The targeting entity can range in size from a small molecule (eg.
receptor ligand), to a larger molecule such as a monoclonal antibody. The identification
of this entity is usually performed using library based screening, phage display or in
silico (ligand screening).14,

26

Depending on the properties of the molecule and the

modality of choice, a signaling ligand is then bound to the selected targeting entity. For
nuclear imaging, radioisotope labeling, typically carried out by chelation or covalent
coupling reactions, is required.27 Optical imaging on the other hand, requires organic
fluorophores or inorganic compounds, such as quantum dots, for fluorescence imaging, or
naturally occurring substrates for bioluminescence optical imaging.28
The designed imaging probe should also possess the appropriate characteristics in
order to bypass all biological barriers (Figure 1.6) and reach the target of interest, within
a reasonable time period, in sufficient concentration. The most important properties of the

8
developed probe in vivo are absorption, distribution, metabolism, and elimination
(pharmacokinetics). In order to leave the vascular system, the vascular walls would need
to be traversed. Lower molecular weight imaging probes can extravasate and be
distributed in both target and non-target tissues, thus decreasing signal to noise ratios.
Extravasation, however, is not always feasible. While tumors or inflammatory tissues
with leaky vasculature are easier to traverse, traversing the blood brain barrier tends to be
less permissible. Once the probe crosses over into the targeted tissue, it would have to
overcome other barriers, such as steric issues preventing proper probe delivery, in order
to reach the targeted cell.14, 17, 29, 30

Figure 1.6 Examples of biological barriers that could prevent proper delivery of an
imaging probe.2, 14, 17

1.4 Targeting Component
As discussed earlier, the targeting entity can range in size from a small molecule
(eg. receptor ligand), to a much larger molecule such as an antibody. The work presented
in this dissertation concerns the use of peptide-based compounds as the targeting
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component for the development of molecular imaging probes. The use of peptide
derivatives and their applications are discussed in detail below.
Receptor targets used for peptide-based radiopharmaceuticals are most commonly
among the family of seven transmembrane proteins, often referred to as G-proteincoupled receptors (GPCRs). This family contains the largest class of human receptors of
pharmacological importance, consisting of approximately 50% of reported clinically
relevant drugs acting on its protein members. Advances in proteomics and genomics have
led to the discovery of several hundred GPCRs, some of which have been reported to
have peptide-based endogenous ligands. Some of the most promising examples of
peptide-based drugs and imaging agents are directed towards the somatostatin and
bombesin receptor family. Peptides have been extensively utilized as drug candidates in
two basic categories namely peptides directed towards tumor cell-surface receptors
(Table 1.2) and those targeted towards tumor vasculature.31-44

Peptide
Bombesin / gastrin
releasing peptide
Cholecystokinin
GLP-1
Neurotensin
Somatostatin
Neuropeptide Y
Substance P

GPCR
GRP-R (BB2)

Cancer targets
Prostate

CCK2-R
GLP-1R
NTR1
SST2 (most common)
NPY1
NK1R

Medullary thyroid
Insulinomas
Pancreatic cancer
Neuroendocrine tumors
Breast
Glioblastoma

Table 1.2 Examples of peptides targeting GPCRs.

Tumor vasculature targeting is employed in monitoring processes involved in
tumor growth. Tumor cell proliferation requires enhanced blood supply, making
angiogenesis a necessity in tumor growth beyond 1-2 mm. Enhanced angiogenesis is
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accompanied by over-expression of many biological factors such as integrins, growth
factors and proteases. As a result, a large number of peptide-based imaging probes have
been developed to monitor the over-expression of these biological factors during the
progression of angiogenesis.45, 46 Examples include peptides containing the αvβ3-integrin
targeting moiety Arg-Gly-Asp.47
As targeting agents, peptides provide a number of advantages over other
molecules, which is particularly accentuated when considering their synthetic route and
diversity. Synthesis of peptides using automated solid-phase methodologies allows for
rapid production of analogues in a reasonable time frame. The commercial availability of
unnatural amino acids, further extends the chemical diversity of peptides prepared by this
methodology. Furthermore, peptide-based probes have shown to have lower antigenicity,
rapid access to tumors, enhanced tumor penetration, as well as faster clearance rates.31
Major drawbacks associated with using peptide-based compounds include poor
oral bioavailability and poor metabolic stability. Fortunately, the former is not a major
concern in oncology as most radiopharmaceuticals are administered intravenously. In
addition, the metabolic stability of peptides in vivo has shown to improve using a variety
of structural modifications known to prevent enzymatic degradation. The design of
suitable and robust peptide-based probes therefore needs to account for the following
considerations: biological stability, target affinity, target specificity, and pharmacokinetic
characteristics. Steps in this methodology include design, synthesis and biological
evaluation of the best peptide candidates. Initial biological evaluation analysis could
consist of competitive binding assays or cell-based assays, with a focus to create probes
with high affinity and specificity for the desired protein target. Additional studies will
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then aid in creating a molecule exhibiting biological stability. While results obtained
from in vitro analyses do not necessarily reflect those from in vivo studies, they are
certainly a reasonable starting point in screening for successful candidates. In the next
stage, the pharmacokinetics of developed peptide candidates are evaluated in vivo.31

1.5

Labeling Techniques

1.5.1 Fluorophore Labeling
Fluorescent dyes are commonly conjugated onto biological compounds using
either coupling reactions (eg. amine and an activated carboxylic acid), or direct
nucleophilic reactions between a reactive group (eg. amine, thiol, alcohol) and a
fluorophore. One of the most utilized groups, especially in peptide chemistry, are amines
which are reasonably nucleophilic above pH 8.0 and can be reacted with activated
fluorophore esters, such as N-hydroxysuccinimide (NHS) ester, with high yields and
reproducibility.48 Activated esters, such as the NHS esters, typically exhibit high
selectivity towards aliphatic amines, while having low reaction rates with aromatic
amines, alcohols and phenol. Fluorophore conjugation to amines can also be carried out
using isothiocyanates, which are routinely employed in conjugation of fluorescein
derivatives. In the absence of a reactive amine, thiols could also be utilized in such
reactions. This is achieved via maleimide-thiol reaction at pH 7. Handling of thiolcontaining compounds, however, is more tedious in the presence of multiple thiols, which
could lead to the formation of disulfide bridges. In these situations, addition of a reducing
agent such as dithiothreitol (DTT) is required.49 Table 1.3 lists examples of commercially
available dyes used for conjugation of fluorescein.50-54
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Compound
Fluorescein

Structure

6-[Fluorescein-5(6)carboxamido]hexanoic acid Nhydroxysuccinimide ester

Fluorescein 5(6)-isothiocyanate

N-(5-Fluoresceinyl)maleimide

Table 1.3 Examples of commercially available fluorescein derivatives directed towards
reactions with amines and thiols.

1.5.2 Radionuclide labeling
Radioisotope labeling reactions can be organized into six general categories,
which are isotope exchange, recoil labeling, excitation labeling, biosynthesis, direct, and

13
bifunctional chelator/prosthetic group labeling. In radioisotope exchange reactions, one
or more atoms in a molecule are replaced by their radioactive counterparts. Considering
that these molecules (pre and post labeling) are identical, with the only exception being
an isotope effect, it is expected that they would possess the same biological and chemical
properties. Examples of radiolabeled compounds produced by isotope exchange are

125

I-

triiodothyronine, and 125I-thyroxine.55
Recoil, excitation and biosynthesis labeling methods are not within the scope of
this work. However, in brief, recoil labeling utilizes recoil atoms, produced in a nuclear
reaction, to generate radiolabeled compounds. Unfortunately, the high energy of these
particles results in poor yields and low specific activity. An example of such a reaction is
6

Li(n,α)3H, where the compound to be labeled is mixed in with a lithium salt and

subsequently irradiated in the nuclear reactor. Similarly, excitation labeling entails the
utilization of radioactive daughter ions in a nuclear decay process to label compounds of
interest. An example is the decay of

77

Kr to

77

Br. In this reaction, exposure of the

compound of interest to 77Kr results in labeling with 77Br. Biosynthesis is a process where
a living organism is grown in a culture medium containing the radioisotope of interest. In
this methodology, the tracer is incorporated into the metabolites produced by the
metabolic process of the organism and is subsequently separated. Examples of this
process include 60Co and 57Co-labeled vitamin B12.55
Direct labeling methods entail the attachment of a radionuclide to the molecule of
interest without the need for a prosthetic group. An example of such procedure includes
the binding of radionuclides to thiol groups in the targeting molecule. This methodology,
although easy to perform, is difficult to control and may lead to undesired changes in the
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structure, stability, and pharmacokinetics of the labeled molecule.56,

57

The

characterization of compounds produced from this methodology is also extremely
difficult owing to the lack of a complete understanding of the number of donor atoms and
the possible geometry of the incorporated radionuclides.55 A more precise approach,
perhaps, is radiofluorination which is carried out via nucleophilic or electrophilic
routes.58
The last methodology, which is now the most utilized, is an indirect radiolabeling
approach, where a prosthetic group or a radiometal chelator containing the radionuclide,
is conjugated onto the biological compound of interest. This methodology, most widely
employed in radiolabeling of peptides and proteins, takes advantage of reactive functional
groups naturally present in these compounds for covalent attachment of the radionuclide
containing moiety. Once again, several types of conjugation groups can be used such as
active esters, isothiocyanates, maleimides, hydrazides, and α-haloamides (Figure 1.7).
The choice of the conjugation group is widely dependent on the reactivity and ease of
product isolation. For instance, water soluble NHS-esters could be used for conjugation
reactions to water insoluble peptides, in order to facilitate their removal. In the opposing
case, the ether-soluble p-nitrophenyl esters could be used for water soluble peptides.59-61
Bifunctional chelator/prosthetic group methodology can be carried out using prelabeling or post–labeling approaches. In the first approach, the radiolabeling of the
prosthetic group/chelator is carried out initially, which is then followed by covalent
conjugation of this entity to the biological molecule of interest. As the labeling and
conjugation steps are separated, this procedure ensures the proper attachment of the
radionuclide to the chelate moiety. However, the pre-labeling process could interfere with
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the conjugation process, thus further complicating the required purification steps. This
process is also extremely time consuming and laborious and may not be optimal for
short-lived radioisotope labeling. As a result, this approach is less commonly employed
in radiolabeling procedures.59, 62, 63
In contrast, the post-labeling methodology, being most popular, requires the
synthesis of a conjugate that is ready for radiolabeling (eg. metal-chelator peptide
complex). This approach typically results in high yields and is compatible with solidphase or solution phase chemistry. However, harsh conditions are required for effective
labeling of conjugates, which could result in decomposition of starting materials.59 A
group of widely utilized bifunctional chelators are radiometal chelators, which have
recently gained much interest. Examples of some well known chelators include DTPA,
DOTA, TETA, and NOTA (Table 1.4).59
Bifunctional metal chelators are used to connect a radiometal to a targeting
moiety. Metal-chelator complexes have been reported to be very stable both in vitro and
in vivo. Many variations of caged metal chelators have also been reported in order to
further enhance their respective biological stability. An ideal chelator is expected to
coordinate the radionuclide with ease, great stability, and in high yields. The chelator
must also be compatible with the radiometal of choice as it should not result in changes in
oxidation states or redox potentials. DTPA, has been shown to be a strong chelating agent
for trivalent metals such as indium-111.
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Figure 1.7

Examples of reactive group chemistry for conjugation of a prosthetic group
or bifunctional chelator, X; (a) activated ester, (b) isothiocyanate, (c)
maleimide, (d) hydrazide, (e) α-haloamide.59
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Chelator
DTPA

Structure

DOTA

TETA

NOTA

Table 1.4

Examples of radiometal chelators commonly used with Indium-111 and
Gallium-68.
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There have been reports of DTPA conjugation to larger proteins (eg. albumins
and antibodies), as well as smaller peptides such as somatostatin analogues.64-66 The
cyclen

derivatives

1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetracetic

(DOTA),67-71 1,4,7-triazacyclononae-1,4,7-triacetic acid (NOTA),72,

73

acid

and their

analogues, have played an important role in clinical applications as they form very stable
complexes with a variety of trivalent radiometals such as
177

Lu, as well as the divalent radiometals

27

Mg,

47

66,67,68

Ca, and

Ga,

64

86,90

Y,

111

In,

149

Pm,

Cu. TETA (1,4,8,11-

tetraazacyclotetradecane-1,4,8,11-tetraacetic acid), is one of the most well studied
chelating agents for copper in peptide-based targeted radiotherapy (eg. somatostatin
analogues).59, 74, 75

1.5.3 Important Considerations in Radiolabeling
Several factors need to be considered when preparing radiolabeled compounds. A
high radiochemical yield is always desired, especially in cases utilizing short-lived
radioisotopes. The employed radiolabeling approach should result in the formation of the
most chemically stable conjugate, as the stability of the tracer is first and foremost
determined by that of the radionuclide-conjugated entity. Optimization of labeling
reaction conditions (eg. pH, temperature) is a necessity in order to prevent decomposition
of the targeting entity. These conditions, to some extent, also dictate the most accessible
approach for radiolabeling. Radiochemicals could be adsorbed on the inner walls of
containers if they are in a carrier-free environment. In this case, low radiochemical yields
can be avoided by using either silylated containers or those made of quartz. Storage
conditions for the materials would also have to be determined based on the half-life of the
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radioisotope and the overall stability of the compound. Another important variable is
specific activity (the number of decays per amount of product), which is a measure of the
ratio between radiolabeled and non-labeled compounds present in the final product (eg.
non-radiolabeled starting materials). As a result, precautions should be taken to ensure
optimal specific activity products. This value, however, is not always required to be high
since, in certain cases, high levels could lead to product radiolysis (decomposition by
radiation). Separation techniques would also have to be developed for the isolation and
purification of the final labeled compounds as radioactive contaminants are often formed
as byproducts of radioisotope decay.55
The choice of radionuclide is also important and requires consideration in
determining the proper conjugating moiety. Important factors to consider are the half-life
of the isotope, its mode of decay and availability. For diagnostic imaging, the half-life
should be long enough to allow for the synthesis and purification of the desired probe,
while still allowing for the administration of the tracer, its accumulation in the target
tissues, and its clearance through non-targeted organs. At the same time, however, the
half-life of the selected radioisotope should be as short as possible in order to prevent
unnecessary radiation exposure.59

1.6 Imaging Modalities
The most routinely used imaging techniques are nuclear, magnetic resonance,
and optical, which are again categorized according to the type of signaling molecule
used.1,

2, 76

For instance, nuclear techniques use radioactive isotopes, while magnetic

resonance and optical techniques utilize paramagnetic particles and fluorescent tags as

20
the signaling entity, respectively. The choice of the signaling entity, and therefore the
modality, is dependent on the target of interest as it determines the most important
imaging variables, such as sensitivity or resolution (Figure 1.8). The work presented in
this thesis focuses on nuclear and optical techniques, which are discussed in more detail
below.

Figure 1.8

Examples of available in vivo imaging modalities for small animal
imaging.

1.6.1 Nuclear Imaging
Nuclear imaging, or more specifically emission tomography, involves the use of
radioactive isotopes as signaling entities. Two of the most commonly used modalities in
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radionuclide imaging are positron emission tomography (PET) and single-photon
emission computed tomography (SPECT). In both instances, a small quantity (pM) of a
radiopharmaceutical is introduced into the body in order to non-invasively monitor the
physiological functions of interest. The visualization of the radiopharmaceutical is made
possible by detection of gamma rays that are emitted from the radionuclide.2

1.6.2 PET
Radioisotopes that are used in PET decay by way of positron emission. The
emitted positrons then travel a short distance through the body until they come in contact
with electrons. The resulting electron-positron annihilation reaction then leads to the
formation of a pair of anti-parallel 511 keV photons, which are simultaneously detected
by a set of adjacent detectors. The lines outlining the traveled path of photons, and
intersecting adjacent detectors, is referred to as the line of response (LOR). The
cumulative LOR’s are then used to reconstruct the 3D distribution of the positronemitting radiopharmaceutical within the patient (Figure 1.9).77, 78
The sensitivity of PET is in the pM range and is independent of the location and
depth of the probe. Typically, several million cells containing the tracer are required for
proper detection and recording of the event by the PET scanner. The high sensitivity of
PET renders this imaging technique valuable for in vivo visualization of biological
processes. It is worth noting, however, that because all emitted gamma rays in PET
posses the same energy, if two imaging probes containing different radioisotopes were to
be simultaneously injected, it would not be possible for PET detectors to distinguish
them. As a result, imaging tracers have to be administered and processed individually.
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Figure 1.9

Mechanism of photon detection in PET.

As a result of the versatility of PET, there has been a tremendous increase in the
number of PET radiotracers and clinical applications. The most frequently utilized PET
radioisotopes are
radiotracer is
18

18

18

F,

82

Rb,

11

C,

15

O, and

13

N, (Table 1.5) while the most notable PET

F-FDG (Figure 1.10).79 Considered the golden standard in PET imaging,

F-FDG is used in the evaluation of several neoplasms and radiotherapy planning in

various cancers such as those in lung, head and neck. A large number of other
radiotracers are also currently being used in oncologic PET imaging. Some examples of
such probes are listed in Table 1.6.77, 78
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(a)

Figure 1.10 Structure of 18F-FDG.

Radioisotope
Rubidium-82
Oxygen-15
Nitrogen-13
Carbon-11
Fluorine-18
Technetium-99m
Iodine-123
Indium-111
Gallium-67
Iodine-131

Half-life
1.25 min
124 sec
9.96 min
20.4 min
110 min
6.02 hours
13.2 hours
2.83 days
3.26 days
8.02 days

Modality
PET
PET
PET
PET
PET
SPECT
SPECT
SPECT
SPECT
SPECT

Table 1.5 Common radioisotopes used in PET/SPECT imaging.
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Tracer
11 18
C/ F-thymidine
11
C-methionine
11 18
C/ F-choline
11 18
C/ F/tyrosine, ethyltyrosine
18
F-fluorodihydroxyphenylalanine
18
F-fluoro-misonidazole
18
F-fluoro-17-β-estradiol
18
F-fluorouracil
11
C-acetate

Measured Variables
DNA synthesis
Protein synthesis
Cell-membrane metabolism
Natural amino acid transport
Dopamine synthesis, natural
amino acid transport
Tissue hypoxia
Estrogen-receptor status
Tumor uptake of 5-fluoro-uracil
Lipid synthesis

Table 1.6 Examples of PET tracers used in oncology.77, 79-88

1.6.3 SPECT
PET and SPECT are generally distinguished by the type of radioisotope employed
in their respective imaging probes. While PET makes use of positron emitting
radioisotopes, which lead to the formation of two anti-parallel photons of equal energy,
SPECT employs radioisotopes which emit only a single gamma-ray photon with each
radioactive decay. This distinction between the numbers of emitted photons determines
the type of hardware and software used to detect localized radiopharmaceuticals.77
SPECT imaging techniques, much like PET, start with the administration of a
radiopharmaceutical. Following the decay of the administered radioisotope, gamma rays
are collected by a collimator. This component is typically a thick sheet of a heavy metal,
such as lead, that is shaped like a honeycomb with long thin channels. The collimator
collects gamma rays that travel in the specific direction of the honeycomb channels, and
directs them towards a crystalline material called a scintillator. The scintillator uses the
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energy from the detected gamma rays to produce many optical wavelength photons,
which are detected and converted to a cascade of electrons by a collection of
photomultiplier tubes. The produced current is then acquired by accompanying
electronics which record the occurrence of this event. Registration of multiple events then
leads to the projected image of the object (Figure 1.11). Common radioisotopes used for
SPECT imaging are 99mTc, 111In, 123I, and 131I (Table 1.5).77
Compared to PET, SPECT uses lower energy γ rays, while providing the same
spatial resolution (1-2 mm). Utilization of SPECT also allows for simultaneous detection
of multiple isotopes with varying γ energies. A drawback of SPECT, however, when
compared to PET, is its reduced sensitivity (10-10-10-11 M for SPECT compared to
10-11-10-12 M for PET).2, 77 Clinical applications of SPECT are numerous some of which
have been listed in Table 1.7.

Figure 1.11

Schematic diagram of a conventional gamma camera setup used in SPECT
imaging.77
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Radiopharmaceutical
67
Ga-citrate
111
In-capromab pendetide
201
Tl-TlCl
99m

Tc-sestamibi or tetrofosmin

99m

Tc-MDP
Tc-Red blood cells
99m
Tc-sulfur colloids
99m

99m

Tc-HMPAO

Table 1.7

Application
Infection or lymphoma detection
Prostate cancer detection
Myocardial perfusion or viability
assessment
Myocardial perfusion or viability
assessment, Parathyroid
localization
Metastases or fracture detection
Liver hemangioma detection
Liver/spleen assessment,
lymphoscintigraphy
Brain perfusion assessment

Clinical applications of radiopharmaceuticals used for SPECT imaging;
HMPAO

=

hexamethylpropyleneamine-oxine;

MDP

=

methylene

diphosphonate.89-97

1.7 Radioisotope production
Radioisotopes, in general, can be categorized as being neutron rich or neutron
poor. Isotopes that are neutron rich are produced in a reactor, whereas those that are
electron poor are produced in particle accelerators. The use of the latter, and in particular
cyclotrons, is preferred over the use of reactors. This is due to several reasons which are:
1) unfavorable decay characteristics of reactor produced radioisotopes, such as particle
emissions and gamma ray energies, for certain applications, 2) reactor produced
radioisotopes cannot be produced with high specific activities, and most importantly 3)
access to reactors is more limited when compared to cyclotrons.98 As a result, the
radioisotopes used in this thesis were all produced, either directly or indirectly, by
cyclotron accelerators.

27
1.7.1 Cyclotrons
There are currently a large number of nuclear reactions that can be used in
accelerators to produce radioactive materials. The bombarding particles are usually
protons, deuterons, or helium particles. The energies used range from a few MeV to
hundreds of MeV. In a typical reaction, the accelerated particle, along with its energy, are
absorbed into the nucleus of the target materials. This energy distribution in the nucleus
become homogenous (equilibrates), prior to decomposition and particle emission, thus
leading to the formation of the desired radioisotope. Figure 1.12 shows the setup of a
cyclotron.98
A particle accelerator is surrounded by both inner and outer shields (Figure
1.12 a). The inner shield is approximately 30 cm thick consisting of a mixture of lead,
epoxy, and boron carbide, whereas the outer shield is roughly 70 cm thick and consists of
polyethylene and boron carbide loaded concrete. The cyclotron core, which is always
under high vacuum, consists of two D-shaped electrodes (Figure 1.12 b), to which
alternating voltage is applied. With the aid of an electromagnetic field perpendicular to
the electrodes, charged particles are accelerated in an outward spiral path within the
hollow Ds in the high vacuum environment (Figure 1.12 c). These particles, produced at
the source, can be either positively (eg. H+) or negatively (eg. H-) charged ions. In a
proton cyclotron, hydrogen gas, which is directed into the cyclotron chamber, gets
ionized by electrons emitted from a cathode. This results in the formation of both
positively and negatively charged protons, which are separated based on the type of
cyclotron and the direction of the magnetic field. The energy of the accelerated particles
can reach several MeV depending on the size and design of the cyclotron. After
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acceleration, these particles are then brought in contact with the target materials, causing
the formation of the desired radioisotopes.78, 99 Three cyclotron produced radioisotopes
that will be further discussed in this thesis are listed in Table 1.8.

(b)

(a)

(c)

Figure 1.12 A cyclotron setup with protective shields (a) closed and (b) open; courtesy
of Hamilton Health Sciences; (c) demonstrates components of the cyclotron
core.100
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Radionuclide
Fluorine-18
Indium-111
Germanium-68

Nuclear
Reaction
18
O(p,n)18F
111
Cd(p,n)111In
69
Ga(p,2n)68Ge*

Half life
109.8 min
2.8 days
272 days

Table 1.8 Cyclotron produced radionuclides discussed in this work; *denotes the use of
isotopically enriched materials.98

Among the available radionuclides, the use of short-lived radioisotopes has
gained considerable interest, which is due to the added capability of administering larger
radiopharmaceutical dosages into patients while minimizing their received radiation dose.
This methodology also results in the production of high quality images. The increasing
interest in short-lived isotopes has resulted in the development of radionuclide generators
that serve as convenient sources for their production.98, 101

1.7.2 Radionuclide Generators
Generators are constructed based on the decay-growth relationship between a
long-lived radionuclide and its shorter-lived daughter radionuclide. A long-lived
radioisotope is allowed to decay to its short-lived daughter. Distinct differences in the
chemical properties of the two nuclides are then utilized for the isolation of the daughter
nuclide from the parent. Generators consist of a glass or plastic column fitted at the
bottom with a fritted disk. The parent nuclide is then adsorbed onto the column packing
which could be made of various materials such as cation/anion exchange resin, alumina
or zirconia. Decay of the parent nuclide, and the subsequent formation of its daughter,
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continues until an equilibrium is reached within several half-lives of the daughter nuclide.
Once an equilibrium is reached, the half-life of the daughter would appear to be the same
as that of its parent. The elution of the generator would bring out the daughter while
leaving the parent nuclide adsorbed on the column. After an elution, the daughter nuclide
starts to form again in the generator until an equilibrium is reached, as mentioned above,
at which point another elution can be carried out. Figure 1.13 illustrates the outline of a
radionuclide generator.55

Lead
Shield

Eluent

Column
+
adsorbed
parent
radionuclide

Reaction
Vessel

Figure 1.13 Illustration of a radionuclide generator set-up.

Generators, while simple and convenient to use, provide high yields of the
daughter nuclide reproducibly and are shielded to minimize radiation exposure. The
shipment of generators is facile since they are sturdy and compact, making them ideal

31
candidates for both research and medicinal applications. Table 1.9 provides a list of
generators employed in nuclear medicine.

1.7.3 Optical Imaging
Optical imaging techniques, much like radionuclide imaging, are varied based on
the modality of choice. Traditionally, optical methods were used for surface and
subsurface fluorescence imaging using confocal imaging, multiphoton imaging,

Parent Parent Daughter Daughter
t1/2
t1/2
99
99m
Mo
66 h
Tc
6h
113
113m
Sn
115 d
In
99.5 min
68
68
Ge
271 d
Ga
68 min
62

Zn
137
Cs

9.3 h
30 y

62

81

Rb
82
Sr
191
Os
195
Hg

4.6 h
25.5 d
15.4 d
41.5 h

81m

Kr
Rb
191m
Ir
195m
Au

13 s
75 s
4.9 s
30.6 s

87

80 h

87m

2.8 h

Y

Cu
Ba

137m

82

Sr

9.7 min
2.6 min

Column
Packing
Al2O3
ZrO2
Al2O3; SnO2

Eluant

0.9% NaCl
0.05 N HCl
0.005 M EDTA; 1 N
HCl
Dowex 1 x 8
2 N HCl
Ammonium
0.1 N HCl + 0.1 N
molybdophosphate NH4Cl
BioRad AG 50
H2O
SnO2
0.9% NaCl
BioRad AG1
4% NaCl
Silica gel coated Na2S2O3·5H2O
with ZnS
solution
Dowex 1 x 8
0.15 M NaHCO3

Table 1.9 Examples and specifications of generators used in nuclear medicine.102
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microscopic imaging by intravital microscopy, or total internal reflection fluorescence
microscopy. More recently, however, imaging of deeper tissues has become possible with
the aid of continuous light or with intensity-modulated light and tomographic systems.103
This development has also been largely due to the discovery of near infrared probes that
exhibit deeper tissue penetration, which results from lower tissue light absorption at
longer wavelengths.104 Given all the recent improvements in probe and instrumentation
development, the penetration depth for near infrared dyes is expected to reach up to
several centimeters. However, given the poor depth penetration, optical techniques are
still largely limited to small animal imaging as there are currently few clinical
opportunities.2
Optical imaging techniques have been utilized to study gene expression, cell
trafficking, and drug efficacy. Two techniques utilized in this area are fluorescence
imaging (FI) and bioluminescence imaging (BI), both of which provide a cost-effective
methods for high-throughput screening of biological targets and functions in small animal
models such as mice. Advantages of optical imaging include its high sensitivity, ranging
10-9 to 10-12 M (optical fluorescence imaging), probe stability as there is no radioactive
decay, and its non-ionizing nature. Equally important is the capability to follow multiple
optical probes, labeled with dyes with varying fluorescence wavelengths, in the same
study.2, 105 The particular technique used in this thesis was fluorescence imaging which is
discussed more in detail.
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1.7.4 Fluorescence Imaging
In FI, an excitation light source of a specified wavelength is used to excite a
fluorophore. The subsequent relaxation of energetically promoted electrons then results
in the emission of longer wavelength photons which are recorded by a detector.
Fluorescent probes exhibit great sensitivity due to this discrete emission of light upon
excitation, leading to a number of applications such as those involving in vitro assay
procedures (eg. fluorescently tagged antibodies for antigen detection). In general, each
fluorophore

exhibits

unique

optical

properties

such

as

signal

intensity,

excitation/emission wavelengths, as well as quantum yields (ratio of total photon
emission, over the entire range of fluorescence, to the total photon absorption), and
extinction coefficients. These properties are key components in the design of optical
imaging probes as they determine the type of instrumentation required. A fluorescent
compound is expected to not only possess a high quantum yield, but to also exhibit a
large Stoke’s shift (difference in absorption and emission wavelengths). Greater Stoke’s
shifts minimize interferences from Rayleigh-scattered excitation light, thus resulting in
higher signal to noise ratios. Another important fact to keep in mind when selecting the
appropriate fluorophore, is the naturally occurring background fluorescence of the
surrounding tissues, which could result in the reduction of signal to noise ratios.
Perhaps the most widely used fluorophore is the green fluorescent protein (GFP)
which is often used in in vitro studies such as assays for reporter genes. Other common
classes of fluorescent tags include the fluoresceins, rhodamines, coumarins, BODIPY,
cascade blue, Lucifer yellow, phycobiliproteins and cyanine dyes. Table 1.10 lists
examples of applications of optical imaging.
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Probe
Peptide-based NIR
activatable optical probes
Luciferase, GFP

Application
Cancer imaging, thrombosis, atherosclerosis,
apoptosis, arthritis
Imaging gene expression

Table 1.10 Examples of optical imaging applications in living subjects.106-112

1.8

Imaging Probe Design: Overall Picture
Combination of a targeting moiety, signaling component and imaging modality

for analysis of a particular biological target encompasses the design of an imaging agent.
Over the years, a large number of probes have been reported for use by various imaging
modalities as mentioned above. However, it is not uncommon for a number of probes to
have the same biological target. This is due to the options created from the combination
of targeting moiety, signaling component and imaging modality. As a result, in order to
circumvent this overlap, multimodality imaging was developed for the production of
single molecules that could be used with various modalities, thus maximizing the amount
of data obtained with a single tracer.

1.9 Multimodality Imaging
In recent years, the use of multiple modalities in conjunction has gained
considerable interest. These techniques combine individual strengths of modalities, thus
leading to more accurate imaging results and experiments. The first fused system was a
PET/CT instrument, which was developed by Townsend and colleagues, in collaboration
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with Siemens Medical, in 1998.113 The success of this invention led not only to the
development of other fused systems, but also extensive research in the design of novel
multimodality imaging agents. In the development of multimodality imaging probes,
while not necessitated by all application, use of a single probe for multiple modalities can
aid in maintaining consistent pharmacokinetics and co-localization properties.113 This
would also prevent any additional unnecessary stress on the body, which would
accompany multiple probe administration. Keeping this in mind, over the past two
decades, various types of multimodality imaging agents have been reported with
structures based on lipids (eg. liposomes and lipoproteins),114,
quantum

dots,116

iron-oxide

particles,117

peptides),119 and small molecules.113,

120

dendrimers118),

115

nanoparticles (eg.

macromolecules

(eg.

Of these categories small molecules and

dendrons are commonly used in the development of single and multimodality molecular
imaging probes. These categories are discussed in more details below.

1.9.1 Dendrimers
Dendrimers are an assembly of branched polymers that terminate in numerous
functional groups (eg. hydroxyl or amine groups), which can be further utilized for ligand
conjugation. The more suited biocompatibility of dendrimeric compounds (when
compared to peptides, quantum dots and some small molecules), has resulted in their
increasing utilization in medicinal chemistry.121 Two of the most utilized applications
include drug delivery (eg. cyclodextrins),122 and gene delivery (eg. lysinepolyethyleneglycol-lysine dendrimers).123,124 Peptide-dendrimers have shown to be
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potential candidates as protein mimics, anticancer agents and vaccines. Peptidedendrimers are typically more water soluble, less toxic to normal human cells, and more
stable to proteolysis when compared to their linear analogues. Dendrimeric structures
have also been frequently used in molecular imaging.125
Dendrimers with various tags have already been reported including metal-chelator
complexes (eg. Gd-DTPA),118,

126, 127

and fluorescent tags (eg. rhodamine,128 Alexa

Fluor,142 and Cy5.5129). The branched chains, typically consisting of polyamidoamines
(PAMAM), provide a large number of functional groups on the surface, while
minimizing the overall size of the nanoparticle. For instance, the size of a third generation
(being the number of repeated branched cycles) dendrimer (G3) is approximately 4 nm
while that of a G8 dendrimer is roughly 10 nm. The control over the size of these
particles is very important in determining the pharmacokinetic behavior of the probe in
vivo. For example, the clearance of dendrimers is by the renal system for G3-4
dendrimers, kidney and liver for G5 dendrimers, and only via liver for G6-9 dendrimers.
Figure 1.14 illustrates an example of a dual-modality, dendrimer-based molecular
imaging probe for αvβ3 integrins in a melanoma cell line. The probe exhibited a tumor to
blood ratio of 3.30 ± 0.03, two hours post injection.118, 130

1.9.2 Small Molecules
The synthesis of small molecule multimodality imaging probes is usually
achieved by the direct fusion of multiple imaging probes, or by attachment of multiple
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Figure 1.14

An example of a fluorescent/MR dual-modality imaging probe with the
PAMAM dendrimer core shown in black, gadolinium-EDTA complexes
(MCC), cRGDfK peptide (targeting αvβ3 integrins) TM, and Alexa Fluor
594 dye (Dye).118

38
imaging tags to one molecule. While this design maintains a small size for the probe
overall, it may alter the pharmacokinetics of the parent molecule based on the properties
of the added imaging tags. In terms of probe excretion, small molecules tend to clear via
the renal system, while larger molecules (> 5 nm) typically clear though the liver. This
provides a clear advantage in preventing toxicity associated with long-term liver
retention. While the short circulation times of smaller probes is undesired, resulting in
reduced probe uptake, rapid tissue diffusion rates have been observed and may be
attractive for in vivo applications.113
A number of small molecule probes have already been reported including metalchelator-dye

conjugates

such

as

Gd-DOTA-rhodamine131

and

Gd-DO3A-

spironaphthoxazine132, 133 (Figure 1.14). Although various efforts have been made in the
development of MRI-optical small molecule fusions, there are major disadvantages
associated with this probe design approach. The most important drawback of this
methodology is the much lower sensitivity of MRI when compared to optical imaging
techniques, implying that, in a given probe, higher numbers of MRI tags are required to
produce the same effect as the optical probes. This drawback, however, is minimized in
vivo due to the lowered sensitivity of optical methods compared to in vitro microscopy.
The fusion of radioisotopes with optical tags is a more suitable methodology in designing
multimodality probes because the sensitivities of the involved modalities are in the same
range. Examples of developed optical/nuclear probes include
(Figure 1.15) and radioiodinated porphyrins (eg. HPPH).113, 135, 136

111

In-DOTA-cypate134
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Figure 1.15

Structures of 111In-DOTA-cypate (left) and Gd-DO3A-spironaphthoxazine
(right).

The focus of this dissertation is primarily on the development of novel single and
multimodality molecular imaging probes with an emphesis on PET, SPECT and
fluorescence imaging. Chapter 2 covers the discovery of novel GLP-1-based PET and
SPECT imaging probes for the non-invasive visualization of pancreatic islets in vivo.
Here, syntheses, characterization, radiometal labeling, in vitro and in vivo evaluation (in
mouse models) of novel tracers, are discussed. Chapter 3 deals with the discovery of a
new approach for development of multimodality PET/fluorescence imaging probes. With
the aim of eliminating the need for the attachment of multiple imaging tags in the
development of multimodality agents, the use of porphyrins is suggested as a fluorescent
entity that would also act as a radiometal chelator. The development of a model tracer,
utilizing PPIX as the porphyrin ring of choice, is discussed entailing synthesis,
characterization, radiolabeling, optical analysis, and in vitro characterization with a breast
cancer cell line.

Chapter 4 deals with the development of a screening procedure for the
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discovery of novel biological targeting entities via library screening. This is the first
example of a fluorescent, cell-based approach for the screening of a peptide library where
peptide-based targeting entities can be identified directly, post solid-phase synthesis,
without the need for further modifications. Chapter 5 concludes this dissertation by
discussing future directions for the developed ideas.

1.10
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CHAPTER 2. Design, Synthesis and In Vitro Characterization of
Glucagon-Like Peptide-1 Derivatives for Pancreatic
Beta Cell Imaging
A section of this chapter has been published in the journal of bioorganic and medicinal chemistry
Behnam Azad, B. et al. Bioorg. Med. Chem. 2010, 18, 1265-1272

2.1 Introduction
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia
and disturbance of carbohydrate, fat, and protein metabolism resulting from defects of
insulin secretion, insulin action or both.1 The relative contribution of these variables,
however, varies between different types of diabetes. Several processes are involved in the
development of diabetes including destruction of insulin-producing pancreatic beta cells,
as well as enhanced resistance to insulin action. It is this insensitivity or lack of insulin,
which results in abnormalities typically observed in carbohydrate, fat and protein
metabolism.2 Diabetes has emerged as a major health problem worldwide with an
estimated 285 million people suffering from the disease in 2010. The growth of type 2
diabetes is expected to increase this number to over 400 million in the next twenty years.
Considering the projected statistics, the ability to non-invasively monitor the onset of
diabetes, and its progression into type 2 diabetes, could aid in enhancing our
understanding of the involved processes, thus allowing for earlier diagnosis and
treatment.
Glucagon-Like Peptide-1 (GLP-1) is a peptide hormone produced by intestinal Lcells in response to nutrient ingestion.3 It is produced through the post-translational
processing of its larger precursor, proglucagon, by the enzyme prohormone convertase
1/3 and exists largely as the C-terminally amidated form, GLP-1 (7-36).4
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Other products of this enzymatic degradation are: 1) GLP-2, a peptide involved in
growth of epithelial cells, 2) glucagon for maintaining blood glucose levels, and 3)
glicentin related pancreatic peptide (GRPP), a glucagon precursor (Figure 2.1a ). As
GLP-1 binds to its receptor on the pancreatic beta cell, signaling events trigger the release
of insulin (Figure 2.1b) in a glucose-dependent manner known as the “incretin effect”.5
GLP-1 receptor signaling events also lead to the enhancement of beta cell survival
through stimulation of beta cell growth and differentiation, which plays a role in
regeneration of beta cell mass.6 Therefore, GLP-1 may potentially be a viable and
powerful candidate in the treatment of Type 2 diabetes.

(a)

(b)

Figure 2.1 An illustration showing (a) major proglucagon degradation products and (b)
role of GLP-1 in insulin production.
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The structure of the GLP-1 receptor classifies it as part of the Family B (II)
Glucagon-Secretin G Protein-Coupled Receptor (GPCR) super family. The structural
characteristics of the receptors in this family include a long extracellular N-terminal
domain, disulfide bridged cysteine residues in the extracellular domains, and several
glycosylation sites.7 Structure-function studies of the GLP-1R have shown that the helical
region of GLP-1 interacts with the extracellular N-terminal domain of the GLP-1R, while
the N-terminal 8 amino acids of GLP-1 interact with residues in the extracellular regions
and transmembrane helices of the receptor.8 Such a complex receptor/ligand interaction
demands consideration of only a limited number of sites on the ligand that can be
modified for the generation of an imaging probe with GLP-1 as a targeting component.
Since the structural and biochemical characteristics of the interaction between
GLP-1 and its receptor have been determined, GLP-1 may be a suitable peptide with
which to develop peptide-based imaging probes for the detection and monitoring of
pancreatic beta cell mass in vivo, and thus the onset and progression of diabetes. One
limiting factor is the short biological half life of GLP-1 (1-2 min) due to rapid enzymatic
degradation,7 as the alanine residue at position 8 is a cleavage site for the plasma protease
dipeptidyl peptidase-IV (DPP-IV). Thus, in order to develop GLP-1-based therapeutics
and diagnostics, it is important to increase the biological half life of the parent peptide,
which can be done through modification of 8Ala to 8D-Ala.9, 10 An alternate approach can
be the use of exendin-4, a 39-amino acid peptide originally isolated from Heloderma
suspectum,11 which is a more potent and stable GLP-1R agonist with a plasma half life of
approximately 26 min, largely due to the substitution of a glycine residue for alanine at
position 8.

63
Considering that GLP-1 receptors are expressed on beta cells in high density, we
propose that the use of radiolabeled GLP-1, in conjunction with non-invasive imaging
techniques SPECT or PET, can provide a method of studying beta cell mass in vivo. This
hypothesis is supported by a recent report on the generation of the probe [40Lys (AhxDTPA-111In)NH2]exendin-4, which was shown to target the GLP-1 receptor for the
molecular imaging of insulinomas in transgenic Rip1Tag2 mice.12 In terms of GLP-1
peptides, until now, radioiodination has been the only method reported for GLP-1
radiolabeling. However, iodinated peptides, such as [123I]GLP-1 for detection of
insulinomas, have been reported to be unsuitable as a result of the instability of the
radioiodine label in vivo.13 Here we report radiometal and radiofluorinated derivatives of
GLP-1 with increased structural stability and optimal binding affinity for beta cell
imaging.

2.1.1 Selection of Suitable Metals
Radiometal-labeled ligands have commonly been used in molecular imaging with
both PET and SPECT modalities. Radiopharmaceuticals labeled with metal radionuclides
are typically injected into patients in order to diagnose and monitor biological processes
in cancers, infections, thrombosis, kidney / liver abnormalities, as well as cardiological
and neurological disorders. Radiometal agents are also used to monitor cancer therapy
and targeted radiotherapy treatments. Metals utilized in radiopharmaceuticals range in
half-life from 10 min for 62Ga to several days in case of 67Ga, thus providing a wide range
of options to meet such criteria.14

64
Design of radiometal-based imaging agents requires sufficient understanding of
the redox properties, stability, stereochemistry, charge and lipophilicity of radiometal
complexes because, in most cases, this information would help explain the observed in
vivo behavior of the developed compounds. For instance, the clearance path of negatively
charged compounds is typically through the kidneys, while positively charged
compounds tend to accumulate in the heart. In brain imaging, having an overall neutral
complex is a requirement for crossing the blood brain barrier. Lipophilic complexes have
been commonly observed to clear through the hepatobiliary system with fatty tissue
accumulation. Stereochemistry plays an important role, in temrs of ligand receptor
interaction, when targeting surface receptors.14

2.1.2 Coordination Chemistry of Indium and Gallium
Under physiological conditions, the oxidation state of the group 13 metals indium
and gallium is +3, making it the only relevant oxidation state for radiopharmaceutical
sciences. Complexation of ligands to In and Ga is carried out based on the
hardness/softness of the acid/base.15 While gallium, being slightly harder than indium,
would chelate oxygen, nitrogen or sulfur atoms, indium would prefer neutral nitrogen or
negatively charged sulfur atoms. Coordination spheres of gallium could include 3, 4, 5, or
6 ligands while indium coordination could include up to seven ligands due to its larger
ionic radius. Octahedral complexes of both metals, however, have been reported to be
thermodynamically and biologically more stable.14, 16-18
A major consideration in the chemistry of trivalent indium and gallium is their pH
dependent hydrolysis. Free hydrated Ga(III) is only stable under acidic conditions with
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the insoluble Ga(OH)3 forming as the major product between pH 3 and 9.5. Reactions
carried out in solutions with pH > 9.5 result in the formation of soluble gallate ions
[Ga(OH)4-]. Similarly, free indium(III) is stable in slightly acidic pH solutions (pH = 4-5)
when it exists as a hexaqua ion, while it undergoes extensive hydrolysis below pH 3.4,
and forms soluble hydroxides under basic conditions.19 Considering that the rate of
hydrolysis is much faster than that for metal-complexation, a careful selection of ligands
and optimization of pH levels is a significant requirement. In general, indium(III) and
gallium(III) complexes have been reported to exhibit high thermodynamic stability and
biological inertness (no exchange with transferrin), especially in cases utilizing
multidentate chelators.14, 18

2.1.3 Indium and Gallium Radioisotopes
The metals gallium and indium have several medically useful radioisotopes that
can be used for diagnostic imaging, the most widely used of which are Ga-67 and In111.20 The later has been employed in tumor imaging (111In-DTPA-octreotide),21 tumor
pre-targeting (111In-DTPA-biotin),22 folate receptors imaging (111In-DTPA-folate),23
somatostatin receptor imaging (111In-DOTA-CCK-8),24 thrombus (111In-oxine),25 and
inflammation (111In-white blood cells)26 imaging.14
The use of Ga-68 for positron diagnostic imaging has also gained significant
interest owing to its convenient half-life and its wide availability from radionuclide
generators.27-31 An example of gallium based imaging agents is

68

Ga-Citrate which has

been used in quantification of pulmonary vascular permeability.32 The use of PET allows
quantification that otherwise would not be possible with

67

Ga and gamma scintigraphy.
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There have also been advances in development of radiotracers for myocardial (eg.

68

Ga-

[(4,6-MeOssal)2BAPEN]+),33

68

Ga-

brain

(eg.

68

Ga-THM2BED),34

tumor

(eg.

octreotide),35 and Thrombus (eg. 68Ga-platelets)36 imaging.
As a result, this work employed both indium-111 and gallium-68 in the
development of SPECT and PET oriented molecular imaging probes for beta cell
imaging. Indium-111, produced by the

112

Cd (p,2n)111In nuclear reaction,37 was

purchased, whereas gallium-68 was obtained from an in house Eckert and Ziegler
68

Ge/68Ga radionuclide generator coupled to a modular lab unit for automated synthesis.

2.1.4 Radiometal-Chelator Selection
One class of chelators commonly used for the radiometal labeling of peptides are
cyclen derivatives, such as DOTA,38-40 which are inert and thermodynamically stable,
making them good candidates for radiolabeling of peptides and antibodies.40, 41 Examples
of chelator-conjugated peptides include DOTA-labelled somatostatin analogues (eg.
DOTA-NOC (1-Nal3-octreotide),42 and RGD peptides.43 A review by De LeónRodríguez and Kovacs was recently published on DOTA-peptide conjugates and their
applications.40 To date, DOTA has not been employed as a chelator for the radiolabeling
of GLP-1. The conjugation of DOTA to a peptide using solid-phase chemistry, the most
suitable synthetic approach for peptides, requires ligands that are compatible with the
organic solvents commonly used in solid-phase peptide synthesis (SPPS). The
commercially available tris-tBu-DOTA (Figure 2.2), satisfies these requirements and can
be conjugated, via an unprotected carboxylic acid, to free amino groups using
tetramethyluronium coupling agents such as HBTU (O-benzotriazole-N,N,N’,N’-
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tetramethyl-uronium-hexafluoro-phosphate) or HATU (2-(1H-7-azabenzotriazol-1-yl)1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium). Both indium and
gallium have been shown to form stable complexes with cyclen derivatives. Therefore
tris-tBu-DOTA was selected for chelation of both metals.

Figure 2.2 Structure of tris-tBu-DOTA.

2.1.5 Radiofluorination
Considering the rapid blood clearance of peptides, high signal to noise ratios can
often be achieved in reasonably short time periods. As a result, short-lived PET isotopes
are potential candidates for labeling of bioactive peptides. Fluorine-18, in particular, is an
ideal candidate for such applications with a half-life of 110 minutes, which is also
sufficient for tracer transport. This isotope can be produced in large quantities and
exhibits a low positron energy (0.64 MeV), reducing radiation dose to patients while still
providing high resolution images. Table 2.1 lists commonly used radiofluorinated
peptide-based compounds in oncology.44-52
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Radiotracer
[[18F]-Nle4, D-Phe7]-α-MSH
[18F]-NT(8-13)
[18F]SAA-RGD
[18F]Fluorobenzoyl-RGD
[18F]C-peptide
[18F]-ET-1
[18F]FNleLFNleYK
Table 2.1

Application
α-MSH receptors (eg. melanomas)
NT receptors
αvβ3 integrin expression
Integrin receptors
Specific cell-membrane receptors
Endothelin receptors
Infection/inflammation

Examples of 18F-labeled peptide-based imaging tracers.

Ideal conditions for radiofluorination procedures are given in Table 2.2. The
initial step in all fluorination reactions involves the pre-activation of cyclotron-produced
aqueous [18F]fluoride by evaporation from an added base (K2CO3/Kryptofix-222 and
Bu4N+). Subsequent reactions are then carried out under strong basic conditions, which
are not suitable for compounds containing amine/thiol reactive groups or complex
bioactive molecules. Although, fluorine-18 labeling procedures for peptides are often
time-consuming and laborious, efficient radiolabeling reactions have been reported using
the prosthetic group approach.44 This is especially significant considering that the direct
fluorination of biomolecules is not possible, leading to denaturing and decomposition of
labile substrates.53 Prosthetic groups can be conjugated by various means such as
acylation

(eg.

methyl

2-[18F]fluoropropionate),54

amidation

(eg.

1-[4-

([18F]Fluoromethyl)benzoyl]-aminobutane-4-amine),55 imidation (eg. 3-[18F]Fluoro-5nitrobenzimidate),56

alkylation

(eg.

N-(p-[18F]Fluorophenyl)maleimides),57

and

photochemical conjugation (4-Azidophenacyl-[18F]fluoride).58 Among all prosthetic
groups reported to date, use of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) appears
to be the most suitable approach in radiofluorination of biomolecules as it has been
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reported to result in higher yields and biologically more stable products.58 As a result, the
prosthetic group methodology with [18F]SFB was employed in this work for the
development of GLP-1 based, Fluorine-18 PET tracers.44
Simple, quick and efficient procedure
Few preparation steps
No influence of the labeling agent on the biological activity of the targeting entity
Mild reaction conditions (eg. pH, temperature) to prevent decomposition
Simple radiosynthesis of the prosthetic group
Sufficient chemical reactivity of the prosthetic group
Formation of desired products at tracer concentrations
Minimal side-reactions
Few purification steps

High specific activity product
Table 2.2

Basic requirements of ideal radiofluorination procedures.44

This work utilized both radiometal and radiofluorinated derivatives of GLP-1 in
order to develop probes with enhanced structural stability and optimal binding affinity for
beta cell imaging. Furthermore, various GLP-1 derivatives were prepared in order to
determine the best substitution site for the prosthetic group or chelator to maintain
optimal binding affinity for GLP-1 receptors.

2.2.

Experimental Procedures
Common solvents and reagents were purchased from VWR, Fisher Scientific, or

Sigma-Aldrich and used as received, unless stated otherwise. Sterile, deionized water was
used in all aqueous procedures. All Fmoc protected amino acids, except Fmoc-Lys(mtt)OH (Nova Biochem), and HBTU were obtained from Peptides International. Fmoc-Rink
amide

MBHA

resin (4-(2’,4’-Dimethoxyphenyl-(9-Fluorenylmethoxycarbonyl)-

aminomethyl)-phenoxy-acetamido-norleucyl-4-Methyl Benzhydrylamine

resin),

and
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Boc-His(Boc)-OHDCHA (dicyclohexylamine) were obtained from Nova Biochem. The
hydrophilic linker 2-[2-(2-aminoethoxy)ethoxy]acetic acid (AEEA) was synthesized in
our laboratory.59 DOTA-tris(tBu)-ester was obtained from CheMatech. Indium trichloride
tetrahydrate (99.99%) was obtained from Strem Chemicals. Indium-111 and [125I]exendin were obtained from MDS Nordion and PerkinElmer Inc. respectively.
[18F]Fluoride was obtained from Hamilton Health Sciences. RP-C18 Sep-Pak SPE
cartridges were obtained from Waters. CHO/GLP-1R and INS-1 832/13 cells were
provided by Dr. Michael Wheeler from University of Toronto and Dr. Christopher
Newgard from Duke University respectively. Gallium-68 generator and all automated
synthesis modules were purchased from Eckert and Ziegler.

2.2.1 Peptide Syntheses
Fmoc-based solid-phase peptide synthesis was carried out using an APEX 396
autosynthesizer (AAPPTEC) with 0.05 meq of 0.27 mmol/g Fmoc-Rink amide mBHA
resin and a 3-fold excess of the protected amino acids. Fmoc removal, carried out with
20% piperidine in DMF (N,N-dimethylformamide) over two cycles (10 and 20 min), was
followed by amino acid activation with 3 eq HBTU and 6 eq DIPEA (N,Ndiisopropylethylamine) (10 min) and subsequent coupling over 30 and 120 min cycles.
Methyl trityl deprotection was carried out in a glass peptide reaction vessel using
5% triisopropylsilane (v/v) + 2% trifluoroacetic acid (v/v) in CH2Cl2 over 3 min and
repeated 10 times. Coupling of DOTA/AEEA to this site, or the coupling of DOTA to
AEEA, followed the same methodology used in amino acid coupling, however the
coupling times were increased to 18 and 24 hours for AEEA and DOTA respectively. In
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preparation of fluorescent GLP-1 analogues, conjugation of FITC to Mtt-deprotected
37Lys was carried out using a 4 fold excess of FITC and DIPEA in DMF. This
conjugation reaction was monitored using Kaiser tests and was completed in 23 hours
Microcleaved samples were also used to monitor reaction progress and peptide purity via
HPLC.
Full deprotection of synthesized peptides was accomplished using a solution of
88% TFA (v/v) + 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane (v/v) over 6
hours. The cleaved peptides were then precipitated using tert-butyl methyl ether (TBME)
and centrifuged (2200 rpm for 15 min). After removing the resulting supernatant, the
peptide pellet was rinsed with TBME, vortexed and centrifuged again (2200 rpm for 15
min). The supernatant was removed, then the peptide pellet was dissolved in water,
frozen at 78 oC and lyophilized.

2.2.2 Purification by RP-HPLC / ESI-MS
Peptides were analyzed using a reverse-phase analytical HPLC column (Grace
Vydac Protein/Peptide RP-C18 column 4.6 x 250 mm, 5 μm). This system was equipped
with a Waters 600 controller, Waters Prep degasser, and Waters MassLynx software
(version 4.1). Employed mobile phases were 0.1% CF3CO2H in water (eluent A) and
0.1% CF3CO2H in CH3CN (eluent B). The linear gradient used was 30-50% of B with a
flow rate of 1.5 mL min-1 over 20 min. The column eluate was monitored using a Waters
2998 Photodiode array detector set at 220 and 254 nm.
Peptides were purified using a reverse-phase preparative HPLC column (Grace
Vydac Protein/Peptide RP-C18 column 22.0 x 250 mm, 10 μm) on the same system

72
mentioned above. The detection method along with eluents and gradients were the same
as those stated above, with the exception of the flow rate being set at 20 mL min-1. The
collected fraction was then lyophilized to a solid and subsequently analyzed by ESI-MS
(electrospray ionization mass spectrometry) (Waters Micromass Quattro MicroTM API).
Purity of final products was determined by analytical RP-HPLC (reverse-phase high
performance liquid chromatography).

2.2.3

113/115

In Labeling

In a typical reaction, 5 mg of the GLP-1 analogue, 3 mL of pH 5 NaOAc / HOAc
buffer, and 7 mg of InCl34H2O (0.02 mmol) were placed in a 25 mL glass round bottom
flask. The reactants were dissolved by sonication at 25 oC. The reaction was then carried
out at 70 oC for 30 min. The resulting reaction mixture was allowed to cool before
purification by a light C18 RP sep-pak© (conditioned with 3 mL of ethanol and 10 mL of
H2O). After passing the reaction mixture through the sep-pak©, 10 mL of water was used
as eluent in order to wash out residual unreacted InCl34H2O. A 10 mL aliquot of 0.1%
TFA in CH3CN was used to wash out the labeled product. The resulting solution was then
mixed with 10 mL of H2O (to lower the % component of acetonitrile), frozen at -78 oC
and subsequently lyophilized.
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2.2.4

111

In Radiolabeling

To a clean conical glass vial was added 20 µL of the prepared GLP-1 analogue (1
mg/ mL of pH 5 NaOAc / HOAc buffer). This aliquot was dissolved in 200 µL of the
buffer (10 fold dilution to obtain µM concentrations), to which 5.63 mCi of

111

InCl3 was

added. The reaction mixture was then heated at 70 oC for 30 minutes, before purification
by a RP-C18 SPE Sep-Pak cartridge (conditioned with 5 mL of ethanol and 15 mL of
water). After passing the reaction mixture through the sep-pak©, 10 mL of water was used
as eluent in order to wash out residual unreacted InCl3. A 5 mL aliquot of EtOH was used
to wash out the radiolabeled product. The Sep-Pak eluate was evaporated on a rotary
evaporator prior to in vitro studies. The reaction progress and product purity was
analyzed using analytical RP-HPLC (Waters Symmetry, 4.6 x 150 mm, 5 Å, C-18
column) coupled to a gamma detector. This system employed a Waters 1525 Binary
HPLC pump, Waters 2487 dual  absorbance detector, Waters In-Line degasser and
Breeze software (version 3.30).

2.2.5

69/71

Ga Labeling

In a typical reaction, 10 mg of GLP-1 analogue was dissolved in pH 4 NaOAc /
HOAc buffer. Chelation was carried out using a two-fold excess of anhydrous GaCl3 at
75 oC over 30 minutes. Resulting mixture was cooled prior to purification by a plus C18
RP sep-pak© (conditioned with 6 mL of ethanol and 25 mL of water). After passing the
reaction mixture through the sep-pak©, 10 mL of water was used as eluent in order to
wash out residual unreacted GaCl3. A 6 mL aliquot of EtOH was used to wash out the
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labeled product. The resulting solution was then dried on a rotary evaporator, mixed with
10 mL of H2O, frozen at -78 oC and subsequently lyophilized overnight.

2.2.6

68

Ga Radiolabeling

To a clean glass microwave vessel was added 100 µL of GLP-1 analogue solution
(1 mg/mL in pH 3.5 HEPES buffer). This aliquot was dissolved in 900 µL of the buffer
(10 fold dilution to obtain final solution with µM concentrations), to which 3 mCi
68

GaCl3 was added, freshly eluted from the Ge-68/Ga-68 generator using 3 mL of 0.1 M

HCl. Purification and isolation of 68Ga was achieved using a Phenomenix Strata-X-C 33u
polymeric strong cation exchange column (30 mg/mL) with 0.05 N HCl in Acetone as the
eluent. The reaction mixture was then heated in the reactor of the automated synthesis
module at 80 oC for 30 minutes, prior to sep-pak© purification using a light RP-tC18 SPE
Sep-Pak cartridge© (conditioned with 3 mL of ethanol and 10 mL of water). After passing
the reaction mixture through the sep-pak©, 3 mL of water was used as eluent in order to
wash out residual unreacted

68

Ga materials. A 2 mL aliquot of EtOH was used to wash

out the radiolabeled product. After evaporation of the solvent on a V-10 1.6 Biotage®
vortex and vacuum evaporation system. The reaction progress and product purity was
analyzed using analytical RP-HPLC (SunfireTM RP-C18 column 4.6 x 150 mm, 5 μm)
coupled to a gamma detector, prior to further use in animal studies. HPLC system
employed a Waters 1525 Binary HPLC pump, Waters 2487 dual  absorbance detector,
Waters In-Line degasser and Breeze software (version 3.30).

75
2.2.7 Synthesis of Modified GLP-1 analogue (9)
GLP-1 derivatives were prepared using Fmoc solid phase methodology as
previously mentioned. Glysine 37 was replaced with Fmoc-Lys(Alloc)-OH, while FmocLys(Mtt)-OH residues used in positions 26 and 34 were acylated. In a typical experiment,
0.05 meq of peptide-loaded resin was swollen in DMF. Methyl trityl deprotection of Lys
26 and 34 side chains was carried out in a glass peptide reaction vessel using 5%
triisopropylsilane (v/v) + 2% trifluoroacetic acid (v/v) in CH2Cl2 over 3 min (repeated
x10 ). The resin was washed thoroughly with DMF and DCM respectively. A 7 mL
solution of 10% acetic acid anhydride in DMF was then added to the resin followed by
shaking over 15 min (repeated x5). Completion of acylation reaction (ie. presence of free
amines) was monitored by Kaiser tests. DOTA coupling then proceeded as stated
previously.

2.2.8 Synthesis of [19F]FB-GLP-1
Synthesis of [19F]Fluorobenzoic acid (4-FB) was carried out using a solid-phase
methodology. In a typical synthesis, 0.05 meq of fully protected GLP-1 analogue on rink
amide resin was swollen in DMF over 10 min. Methyl trityl deprotection at position 37
was carried out in a glass peptide reaction vessel using 5% triisopropylsilane (v/v) + 2%
trifluoroacetic acid (v/v) in CH2Cl2 over 3 min (repeated 10 times). In certain instances
Lys(alloc)-OH was employed in position 37. Alloc deprotection was carried out by initial
treatment of the resin with 20 eq of PhSiH3 in DCM for 3 min. This was followed by
addition of 0.25 eq of Pd(PPh3)4 in DCM and mixing over 30 min. This process was
repeated twice prior to prosthetic group conjugation.
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Coupling of 4-FB to this site was carried out using 4 eq of 4-FB and HATU and 6
eq of DIPEA in 5 mL of DMF over 4 hours. Microcleaved samples were used to monitor
reaction progress and peptide purity via HPLC. Full deprotection was accomplished using
a solution of 88% TFA (v/v) + 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane
(v/v) over 6 hours. The cleaved peptides were then precipitated using TBME and
centrifuged (2200 rpm for 20 min). After removing the resulting supernatant, the peptide
pellet was rinsed with TBME, vortexed and centrifuged again (2200 rpm for 20 min). The
supernatant was removed, peptide pellet dissolved in water, frozen at -78 oC and
lyophilized overnight. Purification of the peptide was carried out using a reverse-phase
preparative HPLC column (Grace Vydac Protein/Peptide RP-C18 column 22.0 x 250
mm, 10 μm).

2.2.9 Synthesis of t-butyl-N,N,N-trimethylammoniumbenzoate triflate
In a typical reaction, 700 mg of 4-dimethylaminebenzoic acid was added to 50
mL of THF and cooled to 0 oC for 15 min. This was followed by drop wise addition of
1.3 mL of trifluoroacetic anhydride and stirring for 35 minutes. After addition of 8 mL of
t-BuOH in one portion, the mixture was warmed up to room temperature and stirred over
2 hours. This mixture was then poured into 250 mL of saturated NaHCO3 and extracted
(3x) with dichloromethane. Organic layers were combined, evaporated using a rotary
evaporator, dried with MgSO4 and passes through a silica gel plug. The product was
subsequently eluted using 60 mL of DCM, and evaporated to give a yellow oil. This oil
was redissolved in nitromethane and cooled to -30 oC for 20 min. A 500 µL aliquot of
methyl triflate was then added drop wise to the reaction mixture, which was warmed up

77
to 0 oC and stirred over 1 hour. The reaction mixture was poured into 200 mL of diethyl
ether causing the precipitation of the desired product as a white powder, which was
isolated by suction filtration and washed with cold diethyl ether. The dried product was
analyzed using 1H NMR and was shown to not require further purification. Typically 1 g
of product was obtained indicating a 68% yield.

2.2.10 Synthesis of 4-[18F]FB and 4-[18F]SFB
Prior to the start of reaction, the obtained [18F]Fluoride sample was dried via
azeotropic evaporation with anhydrous acetonitrile. A typical reaction involved the
addition of 5 mg (13 mmol) of the triflate salt to 1 mL of anhydrous CH3CN containing
80 mCi of [18F]Fluoride. The mixture was heated at 90 oC over 10 min. A 500 µL aliquot
of 1 M HCl was added and the reaction mixture heated at 100 oC for 5 min. After cooling,
the mixture was diluted with 12 mL of deionized water and passed through a RP-C18
light Chromafix cartridge. The product was eluted with 7 mL of acetonitrile, followed by
addition of 500 µL of 45% Me4NOH. The solvent mixture was evaporated at 100 oC
under a nitrogen stream and product was assayed and analyzed using an analytical RPHPLC (Waters Symmetry, 4.6 x 150 mm, 5 Å, C-18 column) coupled to a gamma
detector. Decay-corrected radiochemical yields were 35±5% with radiochemical purities
> 98%.
The synthesis of Succinimydyl 4-[18F]Fluorobenzoic acid involved the activation
of [18F]FB with 15 mg of TSTU in 500 µL of anhydrous acetonitrile at 90 oC over 4 min.
After cooling and addition of 10 mL of 5% aqueous acetic acid, the reaction mixture was
passed through a RP-C18 Chromafix cartridge. Unreacted materials were washed out of
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the cartridge using 2 mL of a 65:35 water:acetonitrile solution. The product was eluted
with 3 mL of acetonitrile, dried using a rotator evaporator, assayed and analyzed using an
analytical RP-HPLC (Waters Symmetry, 4.6 x 150 mm, 5 Å, C-18 column) coupled to a
gamma detector. Activation by HATU was carried out using the same methodology.

2.2.11 Solid-phase Synthesis of 37-Lys-[18F]FB-GLP-1(7-37)
Coupling of [18F]FB was carried out on resin using Mtt-deprotected GLP-1
derivative, with HATU in DMF at 50 oC over 15 min. Resin batch was then drained,
washed with DCM, and assayed. Complete deprotection and cleavage from the resin was
then achieved using 90% TFA and scavengers at 50 oC over 20 min. The resulting
cocktail was then evaporated on a rotary evaporator, counted and analyzed by analytical
HPLC as mentioned above. In the case of [18F]SFB, the reaction was carried out (on
resin), in 500 µL of DMF at 50 oC over 15 min. Deprotection, cleavage from resin and
subsequent analysis steps were carried out as mentioned above.

2.2.12 Binding Assays
All GLP-1 receptor binding studies were conducted using Chinese hamster ovary
cells stably transfected with the human GLP-1 receptor (CHO/GLP-1R), generously
donated by Dr. Michael Wheeler (University of Toronto). Receptor binding was
measured by the displacement of [125I]-exendin-4 with increasing concentrations of the
synthesized

113/115

Indium or

69/71

Ga-labeled GLP-1 analogues, using a previously

published method.60 Briefly, CHO/GLP-1R cells were cultured in Dulbecco’s Modified
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Eagle’s Medium (DMEM, Invitrogen) containing 10% fetal bovine serum (Invitrogen).
On the day of the experiment, cells were rinsed 2X with warm Hank’s buffered saline
solution (HBSS) and dissociated in HBSS containing 2 mM EDTA. Approximately one
million cells were incubated for 60 min at 37 oC in binding buffer (DMEM containing
0.1% Trasylol (Bayer) and 0.1% bovine serum albumin (Sigma), pH 7.4), 0.77 µmol
[125I]exendin-4 (Amersham) and variable concentrations of each GLP-1 analogue (10-5 to
10-11 M). After incubation, cells were centrifuged at 2800 rpm for 15 min. After removal
of the supernatants, the cell pellets were washed with 200 µL of cold binding buffer and
re-centrifuged before the final pellet was counted in a gamma counter. Binding curves
and IC50 (half maximal inhibitory concentration) values were generated using MS Excel,
Sigma Plot, and Origin Lab 8.

2.2.13 cAMP Studies
Activation of the GLP-1 receptor by the peptide analogues was assessed by
stimulation of cAMP using a previously published method.60 Briefly, CHO/GLP1R cells
were plated at a density of 1x105 cells/well in a 24-well plate 48 hours prior to the day of
the experiment. Cells were incubated for 30 min at 37 oC in DMEM containing 1 µM 3isobutyl-1-methylxanthine (IBMX; Sigma) and 10 nM of the peptide analogues. Media
were removed, cells were rinsed twice with cold HBSS and scraped in 200 µL of 80%
ethanol. cAMP levels were measured using a cAMP radioimmunoassay kit (Perkin
Elmer, Shelton CT) as per the manufacturer’s instructions. Differences between basal and
stimulated cAMP levels were analysed using a one-way ANOVA followed by Student’s

80
t-test, and differences in fold stimulation were determined using a one-way ANOVA
followed by Tukey’s post-hoc test. Significance was set at p < 0.05 for all analyses.

2.2.14 In Vitro Imaging
INS-1 832/13 cells were plated in 6-well plates at a density of one million cells
per well. Two wells did not receive any radiolabeled peptide; two wells were incubated
with 50 µCi [111In]-8 for 30 min at 37 oC; and two wells were incubated with 50 µCi
[111In]-8 and 1 µM cold exendin-4. After the incubation period, media were removed,
cells were rinsed twice with cold HBSS and covered with 500 L culture media. Cells
were imaged for 30 min with a GE Millenium II gamma camera using a medium-energy
general purpose collimator. Images were acquired and analyzed using GE Xeleris
software.

2.2.15 In Vivo Imaging
In vivo imaging studies were conducted in C57BL/6 mice following tail vein
injection of 0.3-3.5 MBq of 111In- or 68Ga-7. Mice were euthanized 3 min or 4 hours post
injection. The pancreata and other organs were then removed and assayed.
Biodistribution was calculated as % injected dose/g.
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2.3

Results and Discussion

2.3.1 Design of GLP-1 Analogues
The objective of this study was to develop novel GLP-1 analogues exhibiting
optimal binding affinity for GLP-1 receptors thus allowing for the imaging of pancreatic
islets. The primary difficulty in attaching DOTA to GLP-1 is interference with peptidereceptor binding caused by the addition of a metal-complex to the peptide structure.
Therefore, an integral part of this research project was the determination of optimal
attachment sites for the metal chelator in order to circumvent negative impacts on the
binding affinity of the peptide. Figure 2.3 illustrates one of the peptide derivatives before
labeling. Improvement in structural stability of the developed GLP-1 analogues was
achieved by substitution of L-Ala at position 8 with D-Ala, which is a modification
previously reported to increase the resistance of this peptide to degradation by DPP-IV.9
Other substitutions at this position, namely 8Aib, 8Gly, 8Ser, and 8Thr, have also been
reported to increase the structural stability of GLP-1; however, the latter three
substitutions have a negative impact on the binding affinity and potency of the peptide as
an endocrine hormone.61

Figure 2.3 Structure of 37Lys-DOTA-GLP-1.
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A report by Lee and coworkers showed that covalent coupling of PEG
(polyethylene glycol) to specific sites on GLP-1 may improve the overall therapeutic
effect of the peptide while maintaining its biological activity.62 For instance, PEGylated
GLP-1 conjugates, PEG2K-Nter-GLP-1 and PEG2K-26/34Lys-GLP-1, were prepared and
analyzed in vitro. The latter was a mixture of derivatized peptide at positions 26 and 34
which could not be separated. The pharmacokinetic profile of each peptide was studied in
vivo, with the finding that while PEGylation at 34Lys did not increase the biological halflife of the peptide, it did increase its potency in vivo.62 Another report by Madsen and
coworkers explored the structure-activity relationship of Liraglutide analogues, coupled
to fatty acids, with respect to potency on cloned human GLP-1 receptors. The authors
noted that in most cases, long and bulky fatty acids decreased the potency of the
peptide.59 Knudsen et al. reported that GLP-1 can be derivatized at the C-terminal part of
the peptide, with both short/long fatty acids and amino-acid derived spacers, and still
maintain its potency.63
In order to reduce any steric effects imposed by the macrocyclic DOTA ring on
the binding site of the peptide derivatives, a short polyethyleneglycol chain, 2-[2-(2aminoethyl)ethoxy]acetic acid (AEEA), was employed as a spacer to separate the metalchelator complex from the main peptide chain. Considering that this spacer was to be
used at varying sites on the peptide chain, a short PEG-length was selected in order to
minimize negative impacts on the binding affinity of the peptide.63 The AEEA spacer was
synthesized according to a published procedure.64
There have been a number of reports identifying the key residues within the
sequence of GLP-1(7-37) that are critical for optimal binding and proper biological
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functionality. Deletion of the N-terminal 8 amino acids, or substitution of residues within
the N-terminal 10 amino acids, resulted in a dramatic reduction in receptor affinity8, 60.
Alanine scanning experiments have shown that amino acids in positions 7, 10, 12, 13 and
15 were directly involved in receptor binding and activation, whereas those in positions
28 and 29 maintained the secondary structure of the peptide necessary for receptor
recognition.65 These studies therefore highlight the importance of the N-terminal region
of GLP-1 in binding to and activating its receptor. Leger and coworkers synthesized a
number of GLP-1 HSA (human serum albumin) analogues and subsequently tested the
stabilizing effect of bioconjugation in the presence of DPP-IV, as well as receptor
binding and activation.66 From this study, they concluded that the C-terminus is the best
point of modification both in terms of stability, especially with D-Ala at position 8, and
biological activity.66 Figure 2.4 summarizes the results that have been reported on
structure-activity relationships of GLP-1. 67

Figure 2.4 A schematic of the structure activity relationship of GLP-1.

According to the reported Ala scans, structural modification at positions 14, 1618, 20, 22, 27 and 30-35 may be possible without having a major impact on the binding
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affinity of the peptide. The HSA study showed that the only site suitable for side group
modification with bulky ligands is position 37 (C-terminus).66 However, a report on GLP1 PEGylation,62 indicated that positions 26 and 34 could also be functionalized with
bulky ligands without a major impact on binding affinity of the peptide. Therefore, based
on the structure-activity relationships reported to date along with the reported
modifications discussed above, we selected positions 22, 26, 34 and 37 as sites for the
attachment of DOTA to GLP-1. To the best of our knowledge, substitution of large
ligands at position 22 has not been previously reported. The modification of the peptide
at positions 22 and 37 required substitution of Gly (originally at this site), with Lys,
whereas those at positions 26 and 34 already contained a Lys residue.

2.3.2 Synthesis of Indium-GLP-1 Analogues
GLP-1 analogues were synthesized using standard Fmoc-SPPS methods with an
automated multi-well synthesizer. A representative synthetic route is described in
Scheme 2.1, illustrating the preparation of

37

Lys-DOTA-GLP-1(7-37) and the related

analogue containing a spacer between the peptide and the DOTA,

37

Lys-AEEA-DOTA-

GLP-1(7-36). N-Fmoc removal was achieved using 20% v/v piperidine in DMF with the
Kaiser test being used to identify the presence of free primary amino groups, hence
determining the proper duration for Fmoc deprotection. Amino acids with reactive side
chains were protected with acid labile orthogonal protecting groups such as OtBu, tBu,
Trt and Pbf. The site of DOTA attachment, the ε-amine of a lysine side chain positioned
at amino acid 22, 26, 34, or 37, was protected with the temporary protecting group 4methyltrityl (Mtt), which was later removed using a solution of 2% TFA in DCM
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(dichloromethane) with triisopropylsilane as a scavenger. Other lysine residues in the
peptide main chain were protected with Boc groups, which are much less acid labile.
Small samples of the peptide in preparation were taken at varying intervals and, after full
deprotection, were subsequently analyzed using ESI-MS and RP HPLC. Typical yields
obtained for the purified GLP-1 analogues were 10-15%. The purity of the peptides along

Scheme 2.1 Employed synthetic pathway for the preparation of 37Lys-DOTA-GLP-1 and
37

Lys-AEEA-DOTA-GLP-1(7-37): (a) 20% pip/DMF; (b) Fmoc Amino

Acid, HBTU, DIPEA; (c) 2% TFA, triisopropylsilane; (d) Fmoc-AEEA-OH,
HBTU, DIPEA; (e) DOTA(tBu)3, HBTU, DIPEA; (f) 88% TFA +
scavengers.
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with their respective ESI-MS characterization are given in Table 2.3. While purification
of most products resulted in purities in excess of 90%, due to the difficult nature of
preparing these lengthy sequences and the very similar HPLC retention times of peptide
byproducts formed during syntheses, compound 5 was obtained with only an 85% purity.
Initial labeling experiments were carried out using naturally occurring indium113/115 (Scheme 2.2), in order to obtain IC50 values, synthesize HPLC standards, and
determine radiolabeling conditions while preventing unnecessary exposure to radiation.
High temperatures are required for this reaction in order to speed up the formation of the
product. In addition, a sodium acetate buffer was employed in order to maintain the pH at
the desired level, thus preventing the formation of insoluble indium oxides.68 Products
were purified using preparative HPLC and subsequently characterized using ESI-MS,
which in all instances indicated complete labeling of peptides. Final compounds were
analyzed by RP-HPLC for purity determination prior to biological evaluation.
In total, eight novel GLP-1 analogues containing indium were prepared, with four
positional variations (22, 26, 34, 37), each position being prepared with and without the
AEEA spacer. Figure 2.5 illustrates examples of UV and MS spectra obtained for
compound 7.
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#

Peptide

1
2
3
4
5
6
7
8

22

Lys-In-DOTA-GLP-1(7-36)
Lys-AEEA-In-DOTA-GLP-1(7-36)
26
Lys-In-DOTA-GLP-1(7-36)
26
Lys-AEEA-In-DOTA-GLP-1(7-36)
34
Lys-In-DOTA-GLP-1(7-36)
34
Lys-AEEA-In-DOTA-GLP-1(7-36)
37
Lys-In-DOTA-GLP-1(7-37)
37
Lys-AEEA-In-DOTA-GLP-1(7-37)
22

Purity
(%)
90.0
98.0
95.0
90.0
85.3
97.0
98.0
95.3

Calculated
(m/z)
1290.2 [M+3H]3+
1339.4 [M+3H]3+
1266.6 [M+3H]3+
1314.9 [M+3H]3+
1266.6 [M+3H]3+
1314.9 [M+3H]3+
1309.3 [M+3H]3+
1357.6 [M+3H]3+

Observed
(m/z)
1290.3 [M+3H]3+
1340.3 [M+3H]3+
1265.8 [M+3H]3+
1314.6 [M+3H]3+
1266.3 [M+3H]3+
1314.6 [M+3H]3+
1309.5 [M+3H]3+
1357.4 [M+3H]3+

Table 2.3 Analysis of synthesized In-GLP-1 analogues by ESI-MS and RP HLPC.

Scheme 2.2 Indium labeling of DOTA-GLP-1 derivatives.
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(a)

(b)

Figure 2.5 (a) UV and (b) MS spectra obtained for compound 7 post purification.

89
2.3.3

In Vitro Studies
The purified GLP-1 analogues, labeled with Indium-113/115, were evaluated

using receptor binding assays where the displacement of [ 125I]exendin-4 by the indium
coordinated peptide, on CHO/GLP-1R cells, was used as a measure of the respective
IC50 value. Figure 2.6 shows typical plots obtained from competitive displacement
studies, in this instance for compounds 2, 7 and 8. Table 2.4 shows the obtained IC50
values of all eight peptides.

Figure 2.6

Competitive Displacement of compounds 2, 7 and 8 vs. 125I-exendin-4 on
CHO/GLP-1R cells.
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Table 2.4

Compd

IC50 (nM)

GLP-1 (7-37)
1
2
3
4
5
6
7
8

5±3
598 ± 45
93 ± 7
970 ± 73
2660 ± 129
268 ± 16
573 ± 39
63 ± 4
89 ± 3

cAMP
(pmol/well)
118 ± 22
74 ± 10
159 ± 6

Receptor binding and cAMP measurements for GLP-1 peptide analogues.
The first column shows the IC50 values obtained from in vitro competitive
displacement studies. Peptides 2, 7 and 8 were selected for cAMP studies.
Values for cAMP were calculated as the maximal response to 10 nM
peptide.

The best results for GLP-1R binding were obtained for GLP-1 derivatives
modified at positions 22 and 37. For the peptide with DOTA conjugated at position 37
(7), a favorable IC50 of 63 nM was determined, while the presence of the AEEA spacer at
position 37 (8) decreased the binding affinity of the peptide to 89 nM. This was an
unexpected outcome as the C-terminus of the peptide is the least sterically hindered
position along the peptide chain. Although side chain modification at position 22 has not
been recommended in the past literature, our results indicate that, when coupled with the
proper spacer, modification at this position has minimal negative effect on the binding
affinity of the peptide, as indicated by 2 with an IC50 of 93 nM. Considering that the
original residue at this position,

22

Gly, is predicted to disrupt the helical structure of
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GLP-1,69-71 it is possible that its replacement with

22

Lys may decrease the helical

distortion, thereby allowing the addition of the metal complex with only minimal impact
on its binding affinity to the GLP-1 receptor. The use of the AEEA spacer was also
observed to have a negative impact on the binding affinity of the peptide when it was
coupled to the Lys side chain at positions 26 and 34. This could have been caused by
destabilization of the helical conformation of the GLP-1 derivatives as a result of steric
hindrance or strain caused by the AEEA chain.

2.3.4

cAMP Studies
The production of intracellular cAMP is a measure of GLP-1R activiation.72 As

GLP-1 binds to its receptor on the beta cell, intracellular Gs is activated, resulting in the
stimulation of transmembrane adenylyl cyclases (tmACs) and elevation of cAMP
levels.73 This in turn promotes glucose-dependent insulin secretion. In this study, the
ability of peptides 2, 7, and 8 to activate GLP-1 receptors was assessed by measuring
cAMP levels in response to 10 nM of peptide using a previously published method.60 As
shown in Figure 2.7, all three peptides significantly increased cytoplasmic cAMP
concentrations in CHO/GLP1R cells. Peptide 8 increased cAMP levels to the same extent
as native GLP-1 (32.6-fold vs. 33.3-fold, respectively), while the response to peptide 2
(14.4-fold) and peptide 7 (13.8-fold) was not as great (p < 0.05 compared to the fold
increase by native GLP-1). These experiments therefore demonstrate that these analogues
can act as GLP-1R agonists.
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**

**
*

*

Figure 2.7 In vitro cAMP accumulation in CHO/GLP-1R cells at basal level (white
bars) and following stimulation (black bars) with 10 nM of GLP-1, 2, 7, or
8 (n = 3 for each peptide). **, p < 0.001; *, p < 0.05 (compared to basal).

2.3.5

111

In-Labeling

Based on the accumulated biological data for these novel GLP-1 analogues,
compound 8 was selected for radiolabelling with In-111 and subsequent evaluation in
insulinoma cells. Radiolabeling was carried out in pH 5 NaOAC/HOAc buffer over 30
minutes at 70 °C. The decay corrected radiochemical yield for the preparation of [ 111In]-8
was 60% and the radiopurity was 98%. Monitoring of the reaction progress and
characterization of the
113/115

111

In-labelled peptide were carried out using RP-HPLC with

In-labeled peptide 8 used as a non-radioactive standard for chromatographic

comparison of retention time. Figure 2.8 shows the UV and radiochromatograms
corresponding to this reaction. To further demonstrate the ability to radiolabel these
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DOTA-GLP-1 derivatives, the radiolabeling of 2 was also carried out under the same
conditions as mentioned above. The radiochemical yield and purity in this case were 84%
and 97% respectively. Figure 2.9 shows the UV and radiochromatograms corresponding
to the preparation of [111In]-2.

Figure 2.8

(a)

(b)

(c)

(d)

The HPLC (a) UV chromatogram of the standard unlabeled 8; (b) UV
chromatogram of [113/115In]-8; (c) radiochromatogram of [111In]-8 before
purification; and (d) radiochromatogram of [111In]-8 after Sep-Pak
purification.
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Figure 2.9

(a)

(b)

(c)

(d)

The HPLC (a) UV chromatogram of the standard unlabeled 2; (b) UV
chromatogram of [113/115In]-2; (c) Radiochromatogram of [111In]-2 before
purification; and (d) the radiochromatogram of [111In]-2 after Sep-Pak
purification.

To demonstrate that our [111In]-labeled peptides can be used for imaging, an in
vitro imaging study was carried out using [111In]-8 and the clonal insulin-producing beta
cell line INS-1 832/13, which expresses the GLP-1 receptor endogenously. The planar
gamma camera image in Figure 2.10 demonstrated specific binding of the GLP-1
analogue, as it was displaced by exendin-4. In this image, wells 1 and 2, containing the
binding buffer and INS-1 832/13 cells, were used as a control to measure the background
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noise. Wells 3 and 4, containing INS-1 832/13 cells and [111In]-8, indicated uptake of the
hot peptide. The image of wells 5 and 6 clearly indicated displacement of the hot peptide
by exendin-4 thus further proving that the GLP-1 derivative was taken up by GLP-1R on
the surface of the INS-1 832/13 cells. This imaging study proved [111In]-8 to be a
potential SPECT imaging agent for monitoring pancreatic beta cell mass in vivo.

Figure 2.10

In vitro gamma camera imaging study with INS-1 832/13 cells. Wells 1
and 2 = background control (no probe added); 3 and 4 = [111In]-8; 5 and
6 = [111In]-8 + 10-6 M unlabelled exendin-4 (cold exendin-4 block). Left
image, color contoured; right image, grey-scale.

2.3.6 Synthesis of Gallium-GLP-1 Analogues
Previous in vitro analysis of indium-GLP-1 analogues indicated compounds 2, 7
and 8 to be potential candidates for in vivo SPECT imaging of pancreatic islets.
Development of

68

Ga-GLP-1 analogues was undertaken in order to acquire PET

radiotracers for pancreatic islet imaging. In doing so, both naturally occurring

69/71

Ga-
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and radioactive

68

Ga-labeled analogues were synthesized with compound 7. This

analogue was selected over compound 8 owing to near identical binding affinities and
shorter synthesis time. 69Ga-7 was used as an HPLC standard for the radioactive labeling
experiments. Scheme 2.3 illustrates typical conditions for

69/71

Ga-DOTA chelation.

Characterization of compounds was carried out using an LCMS (ESI) as described for
indium analogues.

Scheme 2.3 Synthetic scheme for 69/71Ga-labeling of GLP-1 analogues.

2.3.7 Gallium-68 Radiolabeling of GLP-1 analogues
The radiometal labeling of GLP-1 compounds was carried out using an Eckert and
Ziegler

68

Ge/68Ga generator connected to a series of synthesis modules, which are

remotely controlled by the user via a process computer (Figure 2.11). This remote access
allows for control of specific instructions pertaining to a synthetic pathway. Scheme 2.4
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shows a graphical representation of a program written for radiolabeling of GLP-1
analogues. Table 2.5 lists the components and their function.

(a)

(b)

Figure 2.11 Depiction of an Eckert and Ziegler modular lab system for
radiolabeling experiments; (a)
automated synthesis unit.

68

68

Ga-

Ge/68Ga generator; (b) modular lab
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Scheme 2.4 Schematic of a program written for 68Ga-labeling of GLP-1 analogues.
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Component

Symbol

Vial

Heater Reactor Module

Three way valves
Cation exchange column
or Sep-Pak©
Squeeze pump

Sterile filters

Monitoring screens

Table 2.5 Description of modular part notations used in Scheme 2.4.

All solutions in this system, exception 0.1 N HCl in vial 1-1 which is transferred
by a pressure pump, are transferred via pressure variance. In a typical experiment,
gallium-68 is eluted from the generator using a squeeze pump and 3 mL of 0.1 N HCl
(vial 1-1). This eluate, which may contain breakthrough of other impurities such as 68Ge,
is then loaded onto a Phenomenix Strata-X-C 33u polymeric strong cation exchange
column for purification. Gallium-68 is then eluted out of the cation exchange cartridge
using 0.4 mL of 0.05 N HCl in 98% acetone (vial 1-3), and carried to the reaction vessel
containing the solution of GLP-1 analogue. After a designated duration of heating, the
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reaction mixture is transferred to a RP-C18 Sep-Pak©. A 2 mL aliquot of sterile H2O (vial
1-6) is then passed through this cartridge in order to elute impurities such as unreacted
Ga-68. The final product is then isolated and eluted using EtOH (vial 1-7) into a clean
sealed glass vessel (vial 1-8). A small aliquot of sterile NaCl solution (0.1-0.5 mL) can
also be added to the final product if required for in vivo studies. A small sample of the
final product is diluted with water (10 fold dilution) prior to analysis by RP-HPLC. The
solvent is then evaporated on a Biotage® rapid solvent evaporator system prior to being
assayed. The choice of solvent and quantities of GLP-1 analogues were optimized in
order to maximize radiochemical yields (Table 2.6). Radiochemical yields were observed
to increase proportionally with increasing peptide amounts. Considering that the use of
larger peptide quantities results in lower specific activities, the maximum quantity of
peptide used was set at 100 µg. Ideal radiolabeling conditions were found to be in a pH
3.5 HEPES buffer utilizing 100 µg of peptide. Figure 2.12 shows typical chromatograms
of labeled peptides.

Solvent
HEPES

H2 O
NaOAc/HOAc Buffer pH 4

Peptide (µg)
10
20
50
100
100
100

Volume (mL)
1
1
1
1
1
1

DC-RCY (%)
0.0
0.8
12.7
74.8
11.0
26

Table 2.6 Optimization of radiometal labeling conditions for GLP-1 analogues.
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(a)

(b)

HPLC chromatograms of GLP-1 analogue 7; (a) UV trace of 69/71Ga-7

Figure 2.12

and (b) radiochromatogram of 68Ga-7 post purification.

2.3.8

In Vivo Studies
Both SPECT (111In-7) and PET (68Ga-7) candidates were studied in vivo in

C57BL/6 mice. Figure 2.13 shows PET images obtained over 60 min after intravenous
injection of

68

Ga-7. Unfortunately, pancreatic islets could not be visualized owing to

tracer accumulation in kidneys, which resulted in high background signal levels. In a
typical study, kidney uptake was observed 4 min post injection, while clearance from
bladder was visible 25 min post injection. Biodistribution data indicated reasonable
uptake levels in the pancreas (Figure 2.14), thus confirming the normalization of probe
signal from the pancreas by the kidney uptake. Lower levels of probe uptake were also
observed in the stomach, liver, lungs and heart. In these studies, specific binding was
confirmed by a follow-up injection of excess exendin-4 immediately after injection of the
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radiolabeled probe. The replacement of the GLP-1 analogue indicated specific binding of
the probe, as also evident in other organs expressing the GLP-1 receptors. Removed
pancreata were also visualized externally using a gamma camera to further confirm the
presence of radiolabeled probe (Figure 2.15).

Figure 2.13

PET images obtained over 60 min after intravenous injection of

68

Ga-7

into a C57BL/6 mouse; accumulation of radiotracer in kidneys and
bladder is observed after 4 min and 25 min respectively.
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Figure 2.14

Biodistribution of 68Ga-7 in C57BL/6 mice (n=6), 4 hours post injection;
blocking was carried out with excess Exendin-4.

Figure 2.15 Ex-vivo gamma camera images of pancreata, hearts and stomachs obtained
from three C57BL/6 mice 4 hours after injection of 68Ga-7.
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Considering that the use of

111

In-7 and

68

Ga-7 was shown not to be ideal for in

vivo pancreatic islet visualization, alternate methods of imaging the islets were sought.
The first methodology involved further modification of the peptide backbone in order to
reduce probe accumulation in kidneys, thus increasing signal to noise ratios. The second
methodology utilized the radiohalogen fluorine-18, thus circumventing the need for
radiometals and radiometal chelators.

2.3.9 Modifying the GLP-1 Peptide Backbone
High uptake of imaging probes in kidneys has been an ongoing problem in
oncology both in terms of therapeutics as well as imaging strategies.74, 75 Previous reports
by Pimm et al. and Behr et al. indicated the cause of this uptake to primarily be the
presence of positive charged basic amino acids such as lysine and arginine.76,

77

As a

result, many attempts have been made by various research groups to neutralize positive
charges in an effort to lower the isoelectric points of compounds under study, thus
reducing probe residence time in the kidneys. Examples of such studies include the use of
2,3,5,6-tetrafluorophenyl glycolate or acylation to neutralize positive charges in anti-Tac
disulfide-bonded variable region side-chain Fv fragments, which led to lower kidney
accumulation while maintaining tumor uptake ratios.78-80 Another example included the
lowering of renal accumulation of

111

In-DTPA-conjugated peptides such as Octreotide,

which was accomplished by increasing negative charges along the peptide backbone (eg.
substitution of phenylalanine by aspartic acids).81, 82 In accordance with this theory, it was
speculated that acylation of lysine residues and substitution of arginine residues for
glycine, may aid in reducing charges in compound 7’s backbone. The selection of
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residues for acylation/substitution was made not only with regards to charge, but also to
residues reported to be essential for binding (Figure 2.4). With the above consideration,
37

Gly was replaced with 37Lys (later used for DOTA conjugation), while Lysine residues

at positions 34 and 26 were acylated. Prepared compounds were synthesized using Fmoc
solid phase strategies. Purification and analysis of peptides was carried out as stated
previously.
In this study, two peptide variations were prepared with the presence of an AEEA
linker being the only differentiating factor between the two molecules. The binding
affinity of peptide candidates was determined using the same previously mentioned cellbased assay methodology, incorporating CHO cells and radioiodinated exendin-4. The
obtained IC50 values were 84.6 ± 6.8 nM for peptide containing AEEA (acyl-8) and 76.0
± 3.9 nM for the peptide not possessing a PEG linker (acyl-7). It was noted that the
presence of a PEG linker did not affect the binding affinity of modified peptides. As a
result, acyl-7 was utilized further for in vivo studies. Radiochemical yield and purity of
68

Ga-acyl-7 were 60 ± 5% and > 95% respectively. Figure 2.16 shows typical PET

images obtained from

68

Ga-acyl-7, clearly indicating a significant reduction in kidney

probe accumulation. These results confirmed that a reduction in the overall positive
charge of peptides would result in lowered probe attenuation in kidneys. Unfortunately,
pancreatic beta cells were still not visible even after reducing kidney retention. A possible
explanation for this observation may be mouse-model dependent GLP-1R expression. As
a result, the expression of GLP-1R in various mouse models are currently being studied
using both radiometal labeled 68Ga-7 and a dye tagged fluorescein-7 analogue. In the later
case, FITC was used as the fluorescent tag of choice and was conjugated to

37

Lys side
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chain, as with DOTA. Studies to examine GLP-1R expression in vivo are currently
ongoing.

Figure 2.16

PET images obtained over 60 min after intravenous injection of 68Ga-acyl7 into a C57BL/6 mouse; accumulation of radiotracer in kidneys was
reduced while showing clearance through the bladder 5 min post injection.

107
2.3.10 Fluorination of GLP-1
The fluorination of large molecules such as peptides is typically carried out using
the prosthetic group methodology, owing to limitations imposed by the use of
nucleophilic fluoride such as high proton affinity.83 Among all available prosthetic
groups, [18F]SFB (N-succinimidyl-4-[18F]fluorobenzoate) appears to be most suited for
use with bioactive molecules and proteins, especially in terms of yields and biological
stability of labeled compounds.58 The synthesis of this prosthetic group involves several
major steps which are 1) radiofluorination of an aromatic precursor, 2) formation of 4[18F]fluorobenzoic acid, and 3) conversion of the free acid to the activated ester. There
have been many reports on optimization of SFB synthesis with the aim of reducing
synthesis time, improving activation step, minimizing purification steps and enhancing
radiochemical yields.48,

58, 84, 85

Wester and coworkers have reported an improved

synthesis, which satisfies the requirements for radiofluorination of biological
compounds.58 Radiofluorination of GLP-1 analogues employed the use of both activated
and non-activated [18F]fluorobenzoic acid analogues using solid phase and solution phase
methodologies

2.3.10.1 Solid Phase Approach
In order to examine the potential of fluorinated GLP-1 analogues as PET
radiotracers for the detection of pancreatic beta cells, synthesis of non-radioactive

19

F-

GLP-1 analogues were carried out. Considering that previous studies on metal-chelaterconjugated GLP-1 analogues revealed compound 7 to be a potential candidate for
attachment of bulky groups, residue 37 was selected as a suitable position for prosthetic
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group conjugation. For this approach, 4-fluorobenzoic acid was conjugated to GLP-1
according to Scheme 2.5. Fluorinated product was analyzed and purified by HPLC and
ESI-MS (Figure 2.17).

Scheme 2.5

Synthetic scheme for 37Lys-(FB)-GLP-1(7-37), 9.

A competitive cell based assay was carried out using CHO cells and
radioiodinated exendin-4. This procedure was identical to those carried out for radiometal
GLP-1 analogues. The binding curve obtained for this peptide Figure 2.18 (a) indicated
an IC50 of 56 ± 6 nM, which is comparable to those obtained for promising radiometal
chelated GLP-1 derivatives. cAMP analysis of 9 confirmed it as a GLP-1 receptor
agonist, as indicated in Figure 2.18 (b). Receptor activation seemed to be more significant
in the case of 9 when compared to that of 7.
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(a)

(b)
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HPLC chromatogram and ESI-MS spectrum of GLP-1 analogue 9.
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(a)

(b)

Figures 2.18

(a) Competitive Displacement of 37Lys-FB GLP-1 vs. 125I-Exendin-4 on
CHO/GLP-1R cells; (b) in vitro cAMP accumulation in CHO/GLP-1R
cells at basal level (white bars) and following stimulation (black bars)
with 10 nM of native GLP-1,
37

37

Lys-In-DOTA-GLP-1(7-37) [A] and

Lys-FB-GLP-1(7-37) [B].

The solid phase synthetic route for the preparation of [18F]-9 is illustrated in
Scheme 2.6. This approach required preparation of t-butyl-N,N,N-trimethylammonium
benzoate triflate (TMABT) as the precursor for radiofluorination. Synthesis of TMABT
started with the protection of the carboxylic acid with t-butyl in order to prevent side
reactions in the next step. Methylation of dimethyl amine was then carried out using
methyl trifluoromethanesulfonate (MeOTf), resulting in the formation of a quaternary
amine suitable for nucleophilic aromatic substitution. TMABT was characterized by 1HNMR spectroscopy (Figure 2.19). Radiofluorination of this compound and subsequent
deprotection by 2 M HCl then resulted in the formation of [18F]FB, which was isolated
using a RP-Chromafix cartridge. Figure 2.20 shows a UV chromatogram of [19F]FB and
radiochromatogram of purified [18F]FB.
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Scheme 2.6 Synthetic scheme for the radiofluorination of GLP-1 analogues using the
solid phase approach.

Figure 2.19

1

H-NMR spectrum of purified TMABT.
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Figure 2.20

HPLC chromatograms for 4-FBA; (a) UV chromatogram of 4-[19F]FBA
and (b) radiochromatogram of purified 4-[18F]FBA.

The synthesis of [18F]FB, starting with TMABT, was optimized on a GE
TRACERlab FX-N automated synthesis unit. Deprotection of [18F]FB was optimal with 2
M HCl when carried out at 100 oC over 10 min. Decay-corrected radiochemical yields of
[18F]FB were 35 ± 3% with radiochemical purities > 98%. The activation of [ 18F]FB, in
situ (Scheme 2.6a) or in a separate step requiring further purification of [ 18F]SFB
(Scheme 2.6b), was carried out with both HATU and TSTU. Activated [18F]FB was
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obtained with the same radiochemical yield and purity as pre-activated [18F]FB (35 ± 3%;
> 98%).
Regardless of the route of activation, however, the extent of conjugation of

18

F-

labeled prosthetic group to GLP-1 peptide analogue was extremely low (< 3%) such that
a radiochemical yield could not be determined. However, based on HPLC integration, a
radiochemical yield of 3% was estimated. These results did not change with temperature,
peptide amount (ie. number of peptide-conjugated rink amide resins), or radioactivity
amounts, indicating this approach to be unsuitable for radiofluorination of GLP-1
analogues. It is speculated that poor coupling yields are due to low concentrations of both
the prosthetic group as well as the peptide, in addition to steric hinderence imposed by
the peptide backbone. As a result, a solution phase synthetic approach was considered.

2.3.10.2 Solution Phase Methodology
Considering results obtained from the last approach, an attempt was made to
increase radiochemical yields by increasing peptide concentration in solution. This study
involved the synthesis of a fully protected peptide with only one available free amine for
reaction with [18F]SFB (Scheme 2.7). Solid phase Fmoc-based synthesis of GLP-1(7-37)
was carried out on acid labile Sieber-amide resin, with Lys(Alloc)-OH at position 37.
Palladium catalyzed removal of Alloc following by complete cleavage of the peptide
from the resin using 5% TFA in DCM over 15 min. The peptide was then precipitated
using t-butylmethyl ether (x2), and dried over night on a lyophilizer. Unfortunately, this
peptide was insoluble in any solvents suitable for radiochemistry, rendering this method
also unsuitable for radiofluorination of GLP-1 analogues.
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Scheme 2.7 Synthetic scheme for the radiofluorination of GLP-1 analogues using the
solution phase approach.

2.4

Conclusion
The objective of this project was the development of novel GLP-1 analogues for

the targeting of GLP-1 receptors on pancreatic beta cells. To this end, we have developed
a number of GLP-1 analogues, all shown to have high affinity for GLP-1 receptors. Three
of the initially developed derivatives, namely compounds 2, 7 and 8, showed optimal IC50
values indicating that positions 22 and 37 of GLP-1 are the most suitable for indium and
gallium-DOTA conjugation. While the presence of the AEEA spacer was beneficial at
position 22, it had a negative impact on the binding affinity of the peptide analogues at
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positions 26, 34, and 37. The SPECT images obtained from the competitive displacement
study between [111In]-7 and exendin-4 in INS-1 832/13 cells further demonstrated the
potential of the developed probes to monitor beta cell mass. In vivo studies were carried
out using

111

In-7 and

68

Ga-7 SPECT and PET probes, respectively. Preliminary data

indicated specific uptake of the probe in the pancreas. Strong probe retention in the
kidneys, however, prevented visualization of the pancreas by both PET and SPECT.
Compound 7 was modified in order to reduce kidney accumulation of the radiotracer.
This modification was successful as it resulted in lowering of kidney retention while
maintaining similar binding affinity to GLP-1R as compound 7. Visualization of the
pancreas, however, was still not possible. After studies with radiometal-chelator-GLP-1
conjugates, attempts were made to synthesize fluorinated GLP-1 analogues. The
fluorinated-GLP-1 was shown to have optimal affinity for GLP-1R while still being a
receptor agonist. Both [18F]FB and activated [18F]SFB were successfully synthesized in
optimal radiochemical yields for radiofluorination of GLP-1 analogues. Coupling of
radiofluorinated prosthetic groups to 37Lys-GLP-1(7-37) was attempted using both solid
phase and solution phase methodologies, however, these methods were found to be
unsuitable owing to low yields and peptide insolubility. This research has resulted in the
development of promising GLP-1 based tracers for the non-invasive imaging of
pancreatic islets in vivo. Research on optimization of uptake and probe clearance from
kidneys is currently ongoing.
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CHAPTER 3.

Development of targeted Gallium-PPIX compounds
for PET / Fluorescence dual modality imaging

3.1

Introduction
Molecular imaging, through non-invasive characterization and quantification of

biological processes at cellular and sub-cellular levels, provides the potential for early
detection and treatment evaluation of numerous disease processes. There are currently a
number of imaging modalities available for such applications, however, the use of
multiple modalities in conjunction has gained considerable interest as it provides more
accurate results owing to the complementary abilities of imaging techniques. This is
particularly important in diagnostic imaging considering that modalities with the highest
sensitivity offer a relatively poor resolution, while those possessing high resolution suffer
from poor sensitivity. Combining modalities provides a way to utilize the respective
strengths from each technique, while circumventing shortcomings, leading to more
reliable results.1
Considering that each modality requires its own imaging tag (eg. radioisotopes for
PET, dyes for fluorescence/optical imaging, contrast agents for CT/MRI) a single
imaging probe was initially required for use with each modality of interest. Following the
discovery of the first fused instrument (positron emission tomography/computed
tomography, or PET/CT), however, research on multimodality imaging probes expanded
exponentially based on the concept that while the use of a single compound for multiple
modalities is not essential for all applications, it is certainly beneficial in terms of
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maintaining consistent pharmacokinetics and localization in vivo. Such agents are most
commonly prepared via attachments of all required imaging tags to one molecule.
Another common route is using the same core compound equipped with different tags,
but synthesized individually for imaging (eg. dye-coupled compound-A vs. radiolabeled
compound-A). The drawback of the first methodology is the significant structural
modifications required to make a single multimodality imaging probe, which could result
in changes in the expected pharmacokinetics and localization behavior of the compound.
In the latter methodology, the disadvantage lies in the structural differences between
probes as a result of differences in the respective imaging tags.1 These structural
differences, on top of altering the properties of the core molecule itself, could also lead to
inconsistencies in imaging results obtained from different modalities. As a result, the
development of probes that can be used for multimodality imaging without the need for
further structural modification is desired. In this regard, using an identical compound for
multimodality imaging would minimize discrepancies observed between modalities and,
as well, aid in preserving the innate properties of the core molecule possessing the
imaging tag. One class of compounds suitable for use in such applications is porphyrins.
Porphyrins, which are naturally occurring compounds shown to play an important
role in living organisms, and their respective derivatives have gained considerable
interest in recent years. They have been used for numerous applications, such as in light
harvesting,2 removal of reactive oxygen species (ROS),3 methanogenesis,4 electron
transfer processes,5 detoxification,6 photodynamic therapy (PDT),7 and respiration.8 Two
porphyrin derivatives, namely Porfimer Sodium and verteporfin are FDA-approved for
PDT treatment of melanoma, as well as a number of cancers including those of lung,
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digestive tract and genitourinary tract.7,

9

Nuclear medicine, however, most commonly

utilizes the optical properties of porphyrins as magnetic resonance imaging (MRI)
contrast agents.10
Structurally, the porphyrin nucleus consists of four pyrrole rings connected by
methine groups (Figure 3.1a). This ring system is very stable and exhibits aromatic
characteristics. Functionalization of this ring leads to formation of other classes of
porphyrins such as phthalocyanines (Figure 3.1b). Porphines typically exhibit a central
cavity measuring approximately 4.1 Å in diameter, which is sufficient for coordination of
a metal ion.11 Transition metals have previously been reported to form very stable
complexes with porphyrin rings (eg. Zn-TPP).12 Examples of such complexes are
naturally present in biological systems, such as haemoproteins (containing iron),
chlorophylls (containing magnesium), and Vitamin B12 (containing cobalt).13

Figure 3.1

Structures of (a) porphine, (b) phthalocyanine, (c) protoporphyrin IX, and
(d) heme.

One of the most abundant porphyrins is protoporphyrin (IX) (PPIX), which is
naturally produced in the heme cycle and is the direct precursor of heme, with an iron
core being the only differentiating factor between the two molecules (Figure 3.1c,d).
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PPIX, having various applications, is most commonly used as a photosensitizer
(produced by exogenous administration of aminolevulinic acid) in PDT for treatment of
skin premalignant and malignant lesions.14,

15

This compound has also been shown to

exhibit anti-bacterial and anti-malarial activity in vitro.16, 17 Furthermore, a recent study
has reported the use of peptide conjugated PPIX as a potential probe for anti-cancer
treatment.18 The authors reported that the attachment of a targeting moiety did not affect
the overall efficacy of PPIX, but did significantly improve its targeting and localization
capabilities.
Considering the favourable fluorescence properties of porphyrins and that the
porphine ring system exhibits a spatially appropriate central cavity for metal chelation,
here we report the development of gallium-PPIX compounds as single molecular entities
with potential application for both fluorescence microscopy and positron emission
tomography (PET) imaging, without the need for further structural modification. The
porphyrin ring, in this case, will act as both the fluorescent tag as well as the metal
chelator, thus allowing for the same identical molecule to be used in conjunction with
different modalities. The use of an identical molecule will preserve the characteristics of
the core compound while reducing any inconsistencies observed in between modalities.
The targeting entity was selected to be an RGD motif which has been well studied and
proven to target the αvβ3 receptors typically over-expressed in a number of cancers such
as breast,19 ovarian,20, 21 and melanomas.22, 23 The radiometal of choice was gallium-68,
which is a generator produced PET radioisotope with a 68 min half-life and 89% positron
abundance accompanied by low photon emission (1.077 MeV, 3.2%). The use of this
radioisotope has gained considerable interest in recent years owing to improvements in
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the performance of commercially available

68

Ge/68Ga generators.24-26 In this paper, we

report the synthesis, characterization, optical analysis, radiolabeling and in vitro
evaluation of Ga-PPIX-RGD compounds as proof of concept for the use of porphyrins as
nuclear/fluorescence dual modality imaging agents.

3.2

Experimental
Common solvents and reagents were purchased from VWR, Fisher Scientific, or

Sigma-Aldrich and used as received, unless stated otherwise. Sterile, deionized water was
used in all aqueous procedures. All Fmoc protected amino acids and coupling agents,
except Fmoc-Lys(mtt)-OH (Nova Biochem), HATU (Nova Biochem), and HBTU were
obtained from Peptides International. Fmoc-Rink amide MBHA resin (4-(2’,4’dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-aminomethyl)-phenoxy-acetamidonorleucyl-4-methyl benzhydrylamine resin) was obtained from Nova Biochem. PPIX was
obtained from Sigma-Aldrich. The hydrophilic linker AEEA was synthesized in our
laboratory according to a previously published procedure.27 RP-C18 Sep-Pak SPE
cartridges were obtained from Waters. 68Ge-68Ga generator was obtained from Eckert and
Ziegler.

3.2.1

Peptide Syntheses
Fmoc-based solid-phase peptide synthesis was carried out manually with 0.05

meq of 0.45 mmol/g Fmoc-Rink amide MBHA resin and a 3-fold excess of the protected
amino acids. Fmoc removal, carried out with 20% piperidine in DMF (N,Ndimethylformamide) over two cycles (10 and 20 min), was followed by amino acid
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activation with 3 eq HBTU and 6 eq DIPEA (N,N-diisopropylethylamine) (10 min) and
subsequent coupling over 30 and 120 min cycles.
Coupling of AEEA to N-terminus of peptides followed the same methodology
used in amino acid coupling, however, reaction time was increased to 16 hours. Coupling
of PPIX was carried out using HATU, in a solution of 1:1:1 (v:v:v) DCM:DMF:DMSO
and over 24 hours. Microcleaved samples were used to monitor reaction progress and
peptide purity via HPLC.
Full deprotection of synthesized peptides was accomplished using a solution of
88% TFA (v/v), 5% H2O (v/v), 5% phenol (m/v), 2% triisopropylsilane (v/v) over 6
hours. The cleaved peptides were then precipitated using tert-butyl methyl ether (TBME)
and centrifuged at 2200 rpm for 15 min. After decanting, the peptide pellet was rinsed
with TBME, vortexed and centrifuged again. Following the removal of the supernatant,
the peptide pellets were dissolved in water, frozen at 78 oC and lyophilized overnight.
In preparing the cyclic peptide, cRGDfV, the straight sequence was initially
synthesized using standard Fmoc-based solid phase synthesis on 0.05 meq of 0.40
mmol/g Fmoc-Alloc(Wang resin)-OAll resin. Allyl ester deprotection was achieved using
20 eq PhSiH3 and 0.25 eq of Pd(PPh3)4 in dry DCM. Following Fmoc removal, the chain
was cyclized on resin using 4 eq of HATU over 4 hours. Cleavage and full deprotection
of peptides followed the above mentioned procedures.

3.2.2

Purification by RP-HPLC / ESI-MS
Peptides were analyzed using a reverse-phase analytical HPLC column (SunfireTM

RP-C18 column 4.6 x 150 mm, 5 μm). This system was equipped with a Waters 600
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controller, Waters Prep degasser, and Waters MassLynx software (version 4.1).
Employed mobile phases were 0.1% CF3CO2H in water (eluent A) and 0.1% CF3CO2H in
CH3CN (eluent B). The linear gradient used was 30-50% of B with a flow rate of 1.5 mL
min-1 over 20 min. The column eluate was monitored using a Waters 2998 Photodiode
array detector set at 220, 254 and 400 nm.
Peptides were purified using a reverse-phase preparative HPLC column
(SunfireTM Prep RP-C18 OBDTM column 19 x 150 mm, 5 μm) on the same system
mentioned above. The detection method along with eluents and gradients were the same
as those stated above, with the exception of the flow rate being set at 20 mL min -1. The
collected fraction was then lyophilized to a solid and subsequently analyzed by ESI-MS
(electrospray ionization mass spectrometry) (Waters Micromass Quattro MicroTM API).
Purity of final products was determined by analytical RP-HPLC.

3.2.3 General procedure for synthesis of 69/71Ga-Labeled peptides
In a typical reaction, 8 mg of the trimeric peptide, RGD, 3 mL of pH 5 NaOAc /
HOAc buffer, and 5 mg of anhydrous GaCl3 (4 fold excess) were placed in a 5 mL glass
microwave reactor vessel. The reactants were dissolved by stirring at 25 oC over 5 min
before the start of the reaction, which was carried out in a microwave reactor at 70 oC for
40 min. The resulting solution was then mixed with 10 mL of H2O, frozen at -78 oC and
lyophilized overnight.
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3.2.4

Optical Analyses
UV absorption data were obtained using a Varian Cary 300 Bio UV-VIS

spectrophotometer. Excitation and Emission data were obtained using a Photon
Technology International QM-4 SE spectrometer equipped with double excitation and
emission monochromators. Extinction coefficients were calculated using the serial
dilution methodology. For this study, UV absorptions at seven different concentrations
(highest concentration having a UV absorption maxima of 1-2) were recorded per
compound. The slope of the resulting graph of concentration versus absorption was then
calculated in order to obtain the value for the molar extinction coefficient. All absorption,
excitation, and emission wavelengths were obtained in DMSO. Quantum yields were
calculated according to previously reported comparative methods (S. Fery-Forgues, D.
Lavabre, Journal of Chemical Education 1999, 76, 1260), using optically dilute samples
(maximum UV absorption intensity 0.1-1) in EtOH and Rhodamine 6G as the standard.

3.2.5

Fluorescence Microscopy using 69/71Ga-PPIX-AEEA-RGD (8)
MDA-MB-435 cells were released from the tissue-culture flask using trypsin and

seeded onto coverslips in a 12-well tissue culture plate. The cells were incubated
overnight in DMEM containing 10% FBS at 37 oC with 5% CO2. Subsequently, the
serum-containing DMEM in each well was removed and replaced with serum-free
DMEM. Cells were incubated with 67 µM of compound 5 (control) or 8 (probe) in a 37
o

C incubator for 1 hour Cells were then washed three times with PBS, fixed with 4%

paraformaldehyde, and mounted with Prolong Gold antifade reagent containing DAPI
(Invitrogen). Images were captured using the Zeiss AxioImager Z1 microscope, and the
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average PPIX intensities in each cell was quantified using Volocity, version 4.0
(PerkinElmer).

3.2.6

Blocking of 69/71Ga-PPIX-AEEA-RGD with cRGDfV
MDA-MB-435-GFP cells were released from adhesion to tissue-cultured flask

using EDTA. Subsequently, cells were resuspended in serum free DMEM and placed in
microcentrifuge tubes. Incubation was carried out with 67µM of 2 or 8 in suspension for
1 h at 37 oC at 56 rpm. Blocking studies were conducted in the presence of 5x excess of
cRGDfV. Cells were washed three times with PBS by centrifugation, re-seeded onto
coverslips, cultured in DMEM and allowed to adhere. Once the cells had adhered to the
coverslips, they were washed once with PBS, fixed with 4% formaldehyde and mounted.
Images were captured using the Zeiss AxioImager Z1 microscope. The average PPIX
intensities in cells were quantified using Volocity, version 4.0 (PerkinElmer).

3.2.7

Radiolabeling to Prepare 68Ga-8
To a clean glass microwave vessel was added 100 µL of PPIX analogue solution

(1 mg/mL in pH 3.5 NaOAc / HOAc buffer). This aliquot was dissolved in 900 µL of the
buffer (10 fold dilution to obtain final solution with µM concentrations), to which 3 mCi
68

GaCl3 was added, freshly eluted from the Ge-68/Ga-68 generator using 3 mL of 0.1 M

HCl. Purification and isolation of 68Ga was achieved using a Phenomenix Strata-X-C 33u
polymeric strong cation exchange column (30 mg/mL), prior to transfer to the microwave
vessel (eluent: 0.05 N HCl in Acetone). The reaction mixture was then heated in a
microwave reactor at 120 oC for 45 minutes, before purification by semi-preparative
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HPLC (SunfireTM RP-C18 column 10 x 150 mm, 5 μm) The reaction progress and
product purity was analyzed using analytical RP-HPLC (SunfireTM RP-C18 column 4.6 x
150 mm, 5 μm) coupled to a gamma detector. This system employed a Waters 1525
Binary HPLC pump, Waters 2487 dual  absorbance detector, Waters In-Line degasser
and Breeze software (version 3.30).

3.3.

Results and Discussion

3.3.1

Probe Design
The primary objective of this project was to develop a single compound that could

be used for both fluorescence and PET imaging without the need for structural
modifications or attachment of multiple imaging tags. To this extent, the desired probe
would employ a porphyrin ring as the inherently fluorescent metal chelator, which would
be used in conjunction with a targeting entity. While PPIX has gained considerable
interest owing to the versatility of its applications to various research areas, it has been
underutilized as an imaging agent. This, in conjunction with its natural occurrence in
biological systems, led us to select PPIX as the porphyrin ring for this study. The
radiometal gallium-68, an efficient positron emitter used in conjunction with PET, was
also utilized. This radiometal is produced from readily available 68Ge/68Ga generators.
Considering that the focus of this project was to show the potential of porphyrins
in dual modality imaging, the characteristics and behavior of the selected targeting entity
had to be well known in order to reduce the number of variables affecting the outcome of
this research. The tripeptide RGD was selected as the targeting entity, as it is a well
established ligand for the αvβ3 integrin, typically over-expressed in a number of cancers
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such as breast,21 ovarian,20 and melanomas.22, 23 RGD containing compounds have been
used in conjunction with several modalities such as PET (68Ga-DOTA-RGD,

18

F-RGD

peptides),28, 29 MR (Iron oxide naoparticle-RGD, Gd-DTAP-RGD)30, 31 and fluorescence
imaging (quantum dot-RGD).32 As a result, the RGD moiety was selected as the preferred
targeting entity for the αvβ3 receptors.
A major drawback in using porphyrin derivatives is the extreme hydrophobic
nature of these compounds, which raises numerous challenges in their handling due to
significantly reduced product solubility. As a result, a short polyethyleneglycol (PEG)
chain was added between PPIX and RGD in order to enhance the overall solubility of the
compound. The PEG linker of choice was Fmoc-AEEA, which was synthesized
according to a previously published procedure.27 The overall design of the probe is shown
in Figure 3.2.

Figure 3.2

Structure of the proposed imaging probe.
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3.3.2

Synthesis of 69/71Ga-PPIX analogues
RGD peptides were synthesized manually using standard Fmoc-SPPS methods.

An example of this methodology is illustrated in Scheme 3.1. Typical yields, obtained
post HPLC-purification, were 60-70% with purities over 95%. It is important to note that
the formation of both PPIX-AEEA-RGD and PPIX-(AEEA-RGD)2 analogues was
observed at the end of the reaction. This was beneficial as this project initially aimed at
studying both of these compounds in order to examine any advantages associated with
having multiple targeting moieties present on the imaging probe. Use of PPIX was also
advantageous towards simplifying this synthetic route due to the presence of two free
carboxylic acids available for acylation. A drawback of this protocol, however, was the
lack of regioselectivity involved with the acylation of PPIX, as two regioisomers could be
produced. Although these isomers cannot be separated due to their very similar physical
characteristics, their presence is not likely to alter the overall localization or fluorescence
of PPIX conjugates in cancer cells.18 As a result, other porphyrin rings could be
employed if a single specific regioisomer is desired (eg. in drug development).
Considering that this project also aimed to study the effects of peptide and linker addition
on the optical properties of PPIX, eight PPIX analogues were synthesized containing one
or more linker/peptide moieties in addition to their gallium-labeled counterparts. The
purity and ESI-MS characterization of the prepared compounds are given in Table 3.1.
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Scheme 3.1

Synthetic pathway for the preparation of PPIX-AEEA-RGD analogues.

# Compound
2
3
4
5
6
7
8
9

PPIX-AEEA
PPIX-(AEEA)2
PPIX-AEEA-RGD
PPIX-(AEEA-RGD)2
69/71
Ga-PPIX-AEEA
69/71
Ga-PPIX-(AEEA)2
69/71
Ga-PPIX-AEEA-RGD
69/71
Ga-PPIX-(AEEA-RGD)2

Table 3.1

Purity
(%)
97.0
96.0
95.0
97.0
98.0
97.0
98.0
98.0

Calculated m/z

Observed m/z

709.4 [M+H]+
853.5 [M+H]+
1037.5 [M+H]+
755.7 [M+2H]2+
775.3 [M+H]+
919.3 [M+H]+
1104.4 [M+H]+
790.3 [M+H+Na]2+

709.2 [M+H]+
853.4 [M+H]+
1037.7 [M+H]+
756.6 [M+2H]2+
775.4 [M+H]+
919.4 [M+H]+
1104.9 [M+H]+
790.3 [M+H+Na]2+

Analysis of synthesized PPIX-RGD analogues by RP-HLPC and ESI-MS.
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Chelation of naturally occurring gallium (Scheme 3.2) was carried out in order to
prepare non-radioactive compounds for in vitro imaging, optical analysis, preparation of
HPLC standards and determination of radiolabeling conditions, while preventing
unnecessary radiation exposure. Chelation of a metal ion to the porphyrin central cavity
requires high reaction temperatures. Metal chelation reactions of porphyrins using
conventional heating methods have been reported to require very long reaction times,
often continuing overnight at elevated temperatures.33 Microwave reactors, however,
have been reported to facilitate metal chelation reactions leading to significantly reduced
reaction times.34-37 As a result, this study employed the use of a microwave reactor in
order to facilitate reaction rates. In addition, a pH 3.5 sodium acetate/acetic acid buffer
was employed in order to minimize formation of insoluble gallium hydrolysis products. 38
It was noted that chelation efficiencies improved with increasing reaction time, reaching
95% completion after 40 minutes of heating at 75oC. Products were purified using
preparative HPLC and subsequently analyzed using ESI-MS.

Scheme 3.2

Synthetic scheme for the preparation of 69/71Ga-PPIX-AEEA-RGD.
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3.3.3

Optical Analysis
Optical properties of compounds 2-9 was studied and compared to the parent

compound PPIX (1) in order to evaluate the potential for fluorescence microscopy. The
observed excitation and emission wavelengths (Figure 3.3) are reported in Table 3.2.
Both peptide/linker conjugation as well as gallium-chelation caused a blue shift in the
excitation wavelengths from 467 nm for native PPIX to 429-437 nm for gallium
coordinated 6-9. A similar trend was observed for emission maxima with an approximate
wavelength decrease of 50 nm from PPIX to the gallium congener. Maximum absorbance
wavelengths did not change significantly ( ~ 7 nm post gallium chelation), while
extinction coefficients were affected by gallium chelation with a greater than two-fold
increase. The quantum yields were consistent pre and post gallium chelation, indicating
that metal-dependent fluorescence-quenching is minimal in these compounds. This is a
particularly important observation since a number of other metals (eg. Mg, Sn, Zn) were
recently reported to quench the fluorescence of PPIX with quantum yields dropping
below 5%,39 while the quantum yields for 6-9 are maintained above 30% (Table 3.2).
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Figure 3.3

(a) absorption (blue) / emission (orange) data obtained for 8; (b) photo of
visible emission of 1-9 under 365 nm light.

# Compound
1
2
3
4
5
6
7
8
9

PPIX
PPIX-AEEA
PPIX-(AEEA)2
PPIX-AEEA-RGD
PPIX-(AEEA-RGD)2
69/71
Ga-PPIX-AEEA
69/71
Ga-PPIX-(AEEA)2
69/71
Ga-PPIX-AEEA-RGD
69/71
Ga-PPIX-(AEEA-RGD)2

Table 3.2

ex
(nm)
467
467
467
441
446
414
420
437
429

em
(nm)
638
638
635
633
632
585
584
593
585

abs
(nm)
406
407
407
407
407
414
415
414
413

ε
(M-1)
17377
11415
12554
15120
11559
42550
41599
32226
47661

Φ
0.37
0.34
0.32
0.42
0.31
0.49
0.33
0.42
0.49

Photophysical data for PPIX derivatives 1-9: excitation, emission,
absorbance maxima wavelengths, extinction coefficients and quantum
yields (experimental details provided in Supplementary Information).
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3.3.4

In Vitro Imaging
In order to demonstrate the potential of these analogues for fluorescence imaging,

8 was evaluated in vitro using the MDA-MB-435 cancer cell line, which over-expresses
the αvβ3 integrin. For this study compound 6 was selected as the negative control, which
is identical to compound 8 with the exception of lacking the RGD targeting moiety. After
incubation of 8 with cells, and subsequent washing, confocal microscopy images were
obtained. The cellular uptake of compound 8 was statistically significant and visually
pronounced, while the signal from the negative control was nominal, with approximately
a 4:1 signal ratio between 8 and 6 (Figure 3.4). Compounds 7 and 9 were very
hydrophobic and therefore were not evaluated in vitro. In order to confirm specific uptake
of 8 to MDA-MB-435 cells, a blocking experiment was carried out using a cyclic RGD
pentapeptide, cRGDfV, which has high affinity for the αvβ3 integrin.40 The statistically
significant displacement of 8 by the blocking moiety demonstrated specific binding of the
probe to the MDA-MB-435 cell line, therefore confirming the specificity of 8 for the
integrin target.
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Figure 3.4 Fluorescence microscopy of 8 in GFP-expressing MDA-MB-435 cells: (a)
uptake of 8 indicated in yellow (left panel), GFP-expressing cells in green
and DAPI stained nuclei in blue (right panel); (b) uptake of negative control
6 in yellow (left panel); (c) cells with no treatment (left panel); (d) quantified
data for uptake of targeted 8 vs non-targeted 6; (e) quantified data for uptake
of 8 vs uptake of 8 in cells treated simultaneously with cRGDfV peptide
(block).
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3.3.5

68

Ga-Labeling

Radiolabeling of compound 7 with gallium-68 was carried out in a microwave
reactor according to Scheme 3.3. Optimal reaction conditions were found to employ a pH
4.5 HOAc/H2O solution with a 45 minute reaction time at 120 oC. The decay corrected
radiochemical yields were typically 30-35% with radiochemical purity >98%. In theory,
chelation efficiency of porphyrins could be improved with increasing reaction periods
and temperatures. In this case, however, peptide instability and hydrolysis of free
gallium-68 were observed with further increment in both variables. Monitoring of
reaction progress as well as characterization of the radiolabeled products was carried out
using RP-HPLC with utilization of compound 7 as the non-radioactive standard. The
desired 68Ga-labeled product was identified by chromatographic comparison of retention
times between radiolabeled and non-radioactive compounds. Figure 3.4 shows
representative UV and radiochromatograms corresponding to this reaction. It is important
to note that there is a retention time difference of 1.5 minutes between starting material
PPIX-AEEA-RGD and final product

68

Ga-PPIX-AEEA-RGD, thus facilitating their

separation by RP-HPLC at the end of reaction. It is also worth noting that the final
product can also be purified using a RP-C18 Sep-pak®. In summary, this study further
confirms the ability of PPIX to act as a gallium-68 radiometal chelator, as well as the
potential of this probe as a PET imaging agent.
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Scheme 3.3

Radiolabeling scheme for compound 8.

Figure 3.5

The HPLC (a) UV chromatogram of the standard unlabeled 4; (b) UV
chromatogram of [69/71Ga]-8; (c) radiochromatogram of the reaction
mixture pre-purification; and (d) radiochromatogram of [68Ga]-8 post
purification.
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3.4

Conclusion
The aim of this study was to develop porphyrin-based analogues as dual modality

fluorescence/PET imaging agents without requiring the attachment of multiple imaging
tags to the molecule. To that end, we have developed derivatives of PPIX-RGD which
can be used for both fluorescence and PET imaging without the need for modification.
Metal chelation conditions were optimized for gallium labeling (both radioactive and
naturally occurring) and the coordination with gallium produced strongly fluorescent
molecules with quantum yields of >30%. The versatility of this approach permits the use
of different targeting entities based on the desired biological target, while allowing for
progression from in vitro evaluation (fluorescence) through to in vivo imaging (PET),
with consistent imaging results between modalities.
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CHAPTER 4.

A cell-based approach for OBOC combinatorial
library screening against cell surface receptors

4.1 Introduction
An initial step in the development of drugs and therapeutic agents is the
identification of compounds that bind the biological target of interest such as enzymes, or
surface receptors. After identification of the molecule of interest, many analogues are still
synthesized in order to optimize biological variables such as activity and lipophilicity.
Discovery and optimization of potential candidates typically involves the evaluation of a
large number of compounds, making this approach an extremely labor intensive and
time-consuming process. In order to facilitate these demands, various chemical and
biological methods have been developed for the generation of combinatorial libraries and
the subsequent screening of compounds therein against biological targets of interest in
order to identify high-affinity ligands.1 Considered one of the most important recent
advances in medicinal chemistry, this approach is currently utilized in major
pharmaceuticals companies as a powerful tool for the discovery of potential agents for
diagnostic and therapeutic applications.2
In general, all library-based methods consist of three key steps which are 1)
preparation of a combinatorial library, 2) screening of compounds against biological
targets, and 3) structure determination of potential imaging/drug candidates. Libraries
may contain various classes of compounds including, peptides,3 oligonucleotides,4
proteins,5 synthetic oligomers,6 small molecules,1 and oligosaccharides.2, 7, 8 Libraries can
be prepared via biological/biochemical or synthetic approaches. For instance, peptides
could be either chemically synthesized or biologically expressed using a phage display
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approach.9 Compounds requiring chemical syntheses are commonly prepared via a solid
phase methodology. Here, the solid support acts as an insoluble and inert material for the
covalent attachment of compounds, thus facilitating isolation and identification
processes.1
There are currently four major but distinct combinatorial library methods. The
first approach is a biological library method such as phase display.10 Here,
peptides/proteins are expressed biologically using genetically modified plasmids. These
compounds are then screened for binding against DNA or protein of interest. A second
approach involves spatially addressable libraries such as the multipin system, which
involves the use of separate polyethylene pins as reaction media for synthesis of
individual compounds.11 A third technique involves synthetic solution library methods
such as affinity capillary electrophoresis (ACE).12 Here, a competitive binding assay is
used in conjunction with ACE, to identify high-binding ligands for the biological target
of interest. The last method is based on the one-bead-one-compound (OBOC)
combinatorial library approach. In this method a large number of variable peptide
sequences are synthesized on solid support in a spatially independent fashion.2,

13

Sequence determination of peptide candidates from this library is then carried out using
mass spectrometry techniques such as MALDI-TOF/TOF.14 There have also been reports
on variations of this approach. An example of this variation entailed the use of peptide
fragments, instead of single amino acids, in the split synthesis of larger peptides.15
Considering that there are cons and pros associated with each approach mentioned above,
selection of a suitable method is case-specific and relies heavily on the target, assay
system and available resources. The work discussed in this dissertation utilizes an OBOC
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approach, in conjunction with deconvolution methods, for screening of a peptide-based
library.
OBOC libraries have been successfully applied to peptides, oligomers and small
organic molecules.2 Libraries employing this approach are typically prepared on resin via
a split synthesis approach, which involves mixing and splitting resins following each
amino acid coupling (Scheme 4.1).16 Products of this process would consist of a vast
number of beads, each containing only one peptide sequence, with various amino acid
sequences. For instance, a library of octameric peptides prepared from a selection of 20
natural amino acids would consist of over 25 billion sequences of peptides. For this
application, beaded polymers have to fulfill certain structural characteristics of which
size, substitution homogeneity (i.e. number of available functional groups on the bead
surface), resistance to cluster formation, and swelling abilities are most important.
Examples

of

common

beads

used

for

such

applications

include

Tentagel

(polyoxyethylene-grafted polystyrene),17 PEG-PS resin,18 and ArgoGel.19 TentaGel
beads, which are PEG-PS based and typically utilized in bead binding assays, exhibit
polyoxyethylene chains between the solid support and synthesized compounds thereby
reducing steric effects imposed by the bead. PEG-PS beads possess polyoxyethylene
chains as means to modify the polymer properties as they make up 70% of the resin
weight. ArgoGel resins have higher substitution levels, which is made possible by
branching of polyoxyethylene groups at the attachment point to the polystyrene core
(Figure 4.1).
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Scheme 4.1

Figure 4.1.

Synthetic pathway for a randomized combinatorial library.

General structures of (a) Tentagel and PEG-PS and (b) ArgoGel-MB-NH2
resins.
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The binding of bead-bound compounds to biological targets can be visualized via
direct or indirect routes. The direct route involves, for instance, the visualization of a
colored target such as a dye20 or a larger target such as a cell.21 Indirect visualization, on
the other hand, involves the use of reporter groups such as enzymes, radionuclides, or
fluorescent probes.2 In both screening processes, non-specific binding should be
minimized in order to increase signal to noise ratios. Binding to an undesirable site can
usually be eliminated, or at least significantly minimized, by using a high ionic strength
buffer (eg. 0.3-0.4 M NaCl), with non-ionic detergent (eg. 0.1% Triton X-100) and
blocking proteins (eg. bovine serum albumin).2
Various screening methods for OBOC combinatorial libraries have been reported.
A common route of identifying lead compounds is a colorimetric-based enzyme-linked
on-bead assay.22 In this approach, peptide-conjugated beads are enzymatically
phosphorylated and subsequently treated with a dye. Lead compounds which would be on
colored beads are then isolated using selective antibodies. Figure 4.2a illustrates typical
appearance of a cell batch in this assay with positive beads appearing darker. Beads could
also vary in color pending on the extent of binding. Beads exhibiting ligands with a
higher biological affinity appear darker (Figure 4.2b). Another method of screening is a
whole-cell on-bead binding assay.23 Direct visualization of cells (6-10 µm in diameter)
binding to ligand-conjugated beads (90-120 µm) is carried out under a microscope. This
method was previously utilized in identifying peptides that bind integrins on prostate
cancer cell lines. Figure 4.2c illustrates a typical example of this procedure for the
identification of compounds binding cell surface receptors. In theory, the OBOC library
approach can also be applied to viral particles, bacteria or yeast given the appropriate use
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of a reporter/signaling group. Table 4.1 lists some biological targets for which OBOC
libraries were utilized in finding high-affinity ligands.

Figure 4.2

(a) Depiction of an OBOC assay with hit beads appearing dark, (b) a
collection of beads with varying color intensity as reflected by ligand
binding, darker colored beads exhibit higher affinity, (c) depiction of a hit
bead in a whole cell on-bead binding assay, showing attachment of
inherently fluorescent cells to the surface of the bead.

While the OBOC library approach allows for the ability to test a large number of
compounds simultaneously but individually, owing to the spatially separable nature of
compounds on beads, it would still be advantageous to combine multiple approaches in
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order to solve specific problems or improve overall screening abilities. Here, we report a
novel and rapid on-bead cell-based method of screening peptide libraries.

Target
Monoclonal antibodies
Lymphoma cells
Streptavidin/avidin
Thrombin
SH3 domain
Dopamine D2 receptors
Organic dyes
Prostate cancer surface integrins
Protease substrate
Protease inhibitor
Tyrosine kinase
G-protein coupled receptors
Anticancer agents
MSH
Carbonic anhydrase

Table 4.1

A list of biological targets for which OBOC combinatorial library assays
were employed in identification of high affinity ligands.2, 13, 20, 21, 23-34

4.2

Experimental

4.2.1. Materials
Common solvents and reagents were purchased from VWR, Fisher Scientific, or
Sigma–Aldrich and used as received, unless stated otherwise. Sterile, deionized water
was used in all aqueous procedures. Fmoc protected amino acids, HBTU, and Tentagel S
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NH2 resin were obtained from Peptides International. N-Fmoc-3-amino-3-(2-nitrophenyl)
propionic acid (Fmoc-ANP) was obtained from Chem-Impex International, Inc.

4.2.2. Peptide Synthesis
Fmoc-based solid-phase peptide synthesis was carried out using an APEX 396
autosynthesizer (AAPPTec, Louisville) with 0.05 meq of 0.26 mmol/g Tentagel S NH2
(90 µm, 0.27 mmol/g) resin. 1.5 meq of Fmoc-ANP and subsequently, a three-fold excess
of the protected amino acids were used in coupling reactions. Fmoc removal was carried
out using a solution of 20% piperidine in DMF (N,N-dimethylformamide) over two
cycles (10 and 20 min). Amino acid activation was carried out with 3 eq of HBTU and 6
eq of DIPEA (N,N-diisopropylethylamine), which was followed by amino acid coupling
over 30 and 120 min cycles. Deprotection of peptide side chains was accomplished using
a solution of 88% TFA (v/v) + 5% H2O (v/v) + 5% phenol (m/v) + 2% triisopropylsilane
(v/v) over 6 h.
Cleavage of peptides from Tentagel beads was carried out using UV irradiation.
All care was taken to prevent light exposure to synthesized peptides prior to ANP-linker
cleavage. For this reaction, approximately 1-3 peptide conjugated Tentagel beads were
placed in 200 µL of MilliQ water in an open-top 384 well polypropylene plate. UV
irradiation was carried out using a 365 nm UV lamp (UV Products, Upland, CA, model
EL25, 8 mWcm−2) over 2.5 hours. Water was added periodically in order to prevent wells
from drying, thus reducing possible peptide decomposition. The resulting peptidecontaining solution was then used for MALDI-TOF/TOF analysis.
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4.2.3. On-bead Cell-based Assay for Screening Peptide Library
The αvβ3 integrin-expressing MDA-MB-435 cells were transfected with green
fluorescent protein. Approximately 1000 beads containing each peptide were equilibrated
with serum-free DMEM in a 12-well plate. MDA 435 cells were detached from the flask
by EDTA and resuspended in serum-free DMEM. Approximately 200000 cells were
added to each well, containing peptide-conjugated beads, and subsequently placed in a
shaking incubator (50 rpm) for 1 hour at 37oC. Beads were then washed twice with PBS,
and imaged under the Olympus IX70 inverted fluorescent microscope. Cells were fixed
onto beads with 3% formaldehyde for 5 minutes at room temperature, and washed twice
with PBS.

4.2.4. High throughput Screening
Beads from each well were inserted into the COPASTM large particle flow
cytometer (Union Biometrica), and sorted into a 96 well plate. The fluorescence intensity
threshold for sorting was defined using non-functionalized Tentagel beads. Beads with
fluorescent intensity higher than the set threshold were sorted into the 96-well plate.
Sorted beads were imaged using an Olympus IX70 inverted fluorescent microscope. Post
imaging, beads were then treated rigorously with ethanol to remove bound cells. Rinsing
with water was carried out several times prior to MALDI-TOF analysis.

4.2.5. MALDI-TOF MS/MS Analysis
In a typical experiment, the exact molecular ion mass [M+H]+ of a peptide was
determined using MS analysis. MS/MS spectra were subsequently recorded for the
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desired molecular ion peak, previously observed by MS. This was then followed by
manual deconvolution of all peptide sequences.

4.3

Results and Discussion
The aim of this project was the development of an improved procedure for the

screening of peptide libraries. To that end, we have devised a methodology wherein
peptide-conjugated Tentagel beads are screened against cell surface receptors and
subsequently sorted, while still attached to cells, based on fluorescence intensity. To the
best of our knowledge, this is the first example of a screening procedure where cells that
are attached to peptide-conjugated beads are directly monitored and screened for lead
compounds in an automated fashion. This automated procedure is especially significant
in reducing time-intensive labor associated with the manual isolation of beads coated
with high-affinity or hit ligands (hit beads). Isolation of hit compounds using magnetic
particles was recently reported,35 however, this approach necessitates conjugation of
magnetic particles (eg. quantum dots), and multiple antibodies in order to find ligands
with optimal binding affinity. Addition of more variables in the screening process (i.e.
multiple large entities), may reduce the overall efficiency of screening as a result of
enhanced non-specific uptake. Furthermore, collection of hit beads with a magnet often
results in entrapment of false beads containing non-targeting compounds, thus requiring a
second screening process where beads are either manually inspected or put through a
flow cytometer for secondary isolation.36 As a result, having an automated procedure,
which only necessitates the presence of peptide-conjugated beads and cells of interest,
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would be greatly beneficial as it provides a more efficient (i.e. less labor-intensive, more
time efficient, more consistent bead isolation) route for finding potential hit compounds.
As a proof of concept for this procedure a small library of seven heptameric
peptides (Table 4.2) were synthesized via Fmoc solid phase methodology, on 90 µm
Tentagel beads, which have been previously reported to be efficient solid support
candidates for preparation of combinatorial libraries. The well studied αvβ3 expressing
cell-line, MDA-MB-435, was utilized in this work. In addition, the pentameric peptide
GRGDS was incorporated in the sequence of all prepared peptides as it has been
previously reported to bind αvβ3 integrins.37-41 The last two amino acids of the prepared
peptides were selected at random in order to more closely mimic a combinatorial library.
A photolabile linker (ANP) was placed between Tentagel beads and the corresponding
conjugated peptides in order to facilitate peptide removal post screening. Employing this
linker allows for complete removal of all acid-labile amino acid side-chain protecting
groups without removing peptides. This is necessitated by the screening process, which
requires the use of fully deprotected, but still resin-bound, peptides. Figure 4.3 illustrates
the general design of the studied peptides.
A COPASTM Biosorter flow cytometer (Figure 4.4) was used as means for highspeed automated analysis and sorting of cell-bead conjugates. This system was initially
designed to analyze and sort living multicellular organisms based fluorescent protein
expression, with rates of up to 100 organisms per second. This work employed the
capabilities of this instrument for sorting and isolation of hit peptides based on the overall
fluorescence intensity of cell-bead conjugates. The inherent green fluorescence of
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Tentagel beads, in this case, did not interfere with the isolation of beads as the signals
obtained from adhesion of GFP-expressing cells was much more pronounced.

#
1
2
3
4
5
6
7
8

Table 4.2

Figure 4.3

Sequence
GRGDSPS
GRGDSYT
GRGDSWK
GRGDSHL
GRGDSVP
GRGDSTW
GRGDSFA
HMYFLLGH

List of prepared peptide sequences for cell-based screening assay.

Illustrates overall design of prepared peptides.
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Figure 4.4

An illustration of a COPASTM Biosorter showing the mechanism of
detection and isolation of fluorescent samples.42

In a typical experiment, GFP-expressing cells were incubated with each peptide
from the prepared library. After rinsing with PBS medium, cells were fixed onto beads
using formaldehyde, which ensured the binding of cells to the surface of beads. This step
was confirmed to be a necessity as untreated cells were observed to dissociate from beads
during the sorting process. Cell-bound beads where then loaded onto the COPASTM flow
cytometer, which isolated hit beads based on fluorescence intensity. Peptides were then
rinsed and cleaved from the resin prior to analysis by MALDI-TOF. Figure 4.5 shows
images of compound 1 taken with an Olympus IX70 inverted fluorescent microscope.
Images indicate a reduction of adhered cells post rinsing, which is due to the clearance of
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non-specific cell uptake. Images of beads post rinsing and sorting were comparable.
Using the same methodology, cell sorting, isolation and imaging for other peptide
candidates in the library was carried out (Figure 4.6). As can be seen, peptides 1, 3, 4
and 7 exhibited highest levels of binding. Peptide 8 was used as a negative control
because of its lack of affinity for αvβ3 integrins. This was further confirmed by the
COPASTM sorter which did not isolate any 8-bound beads.

Figure 4.5

Images of MDA-MB-435 cells adhered to Tentagel beads containing 1
pre-wash (left), post-wash (middle) and post-sorting (right).

Considering that this is the first-reported fully automated cell-based screening
assay, it was deemed necessary to confirm the ability to identify hit peptides both pre and
post sorting. This was especially important in ruling out fragmentation prevention by
residual formaldehyde that could be present after cell sorting. For this reason, MALDITOF/TOF analysis of standard peptides and those post sorting were carried out. In the
former case, synthesized peptides on Tentagel beads were fully deprotected using a TFA
cleavage cocktail containing scavengers. Under a light inverted microscope, 1-3 beads
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Figure 4.6 Images of MDA-MB-435 cells adhered to peptide-conjugated tentagel beads
pre-wash (left columns), post-wash (middle columns) and post-sorting (right
columns).

were separated and placed, with 200 µL of MilliQ water, into one well of an open-top
384 well polypropylene plate. Removal of peptides from the resin was then carried out by
exposure to a 365 nm UV light over 2.5 hours. Water was added periodically in order to
prevent wells from drying, thus reducing possible peptide decomposition. The resulting
peptide-containing solution was then used for MALDI-TOF/TOF analysis. As mentioned
earlier, peptide-conjugated Tentagel beads were fully deprotected, but still bound to
Tentagel beads, prior to analysis by the COPAS sorter. After cell sorting, removal of
peptides from hit beads was accomplished using the same procedures as those used for
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standard untreated beads. All peptide solutions were then analyzed by MALDITOF/TOF. In a typical experiment, the exact molecular ion mass [M+H] + of a peptide is
determined using MALDI-TOF analysis. MS/MS spectra are subsequently recorded for
the desired molecular ion peak, previously observed by MS. This was then followed by
manual deconvolution of all peptide sequences in this work. Fragments were calculated
and reported according to published procedures.43 Figure 4.7 illustrates commonly
observed peptide fragmentation patterns. Missing fragments can be calculated only if the
complementary fragment is observed. Figure 4.8 shows the MS/MS spectrum obtained
for untreated 1, which was used as a standard point of comparison to MS/MS spectra
obtained post cell sorting (Figure 4.9). As it can be seen, differences between MS/MS
spectra of pre- and post-sorted peptides are minimal, indicating that treatment and
handling of cell-peptide-bead conjugates in this methodology does not negatively impact
the peptides. In addition, successful sequencing of peptide candidates confirms the
consistency in sequencing ability pre- and post-sorting (Tables 4.3 and 4.4). Tables 4.54.10 list calculated and observed fragmentation patterns for compounds.
In certain cases N-terminal glycine was not observed and could not be calculated
by complementarity. In these situations the combined molecular weights of the last two
N-terminal residues was calculated to be that of Gly and Arg. The order of the two
residues was determined by considering possible side chain fragmentation of Arg
(Scheme 4.2)44 as well as overall molecular weights of residues. Assuming the Nterminal peptide sequence order, RG, would indicate that the molecular weight
corresponding to arginine should still be observable after glycine fragmentation.
Assuming the N-terminal peptide sequence GR, on the other hand, would indicate that
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upon arginine fragmentation, the remaining molecular weight (i.e. glycine), would be too
low to be definitively observed, as in all cases in this study. Given the lack of evidence
for the presence of arginine or any side chain fragmented derivatives, it was concluded
that the likely order of sequence for the last two N-terminal residues was in fact GR.

Figure 4.7

Common peptide fragmentation patterns and the corresponding fragment
notations.43

Absence of these fragments was especially apparent for peptides 3 and 6 where
even the standard un-treated samples exhibited this pattern (Tables 4.6 and 4.9). Peptides
2 and 7, on the other hand, only displayed this pattern for treated samples, as sequences
for untreated peptides were completely deconvoluted (Tables 4.5 and 4.10). The cause of
this incomplete fragmentation was initially postulated to result from trace amounts of
formaldehyde, previously used in fixing cells, in the final peptide solution used for
MALDI-TOF/TOF analysis. However, fragmentation patterns observed for peptide 4
disproved this hypothesis as the sequence of treated samples, unlike those of standards,
was completely deconvoluted. This pattern, therefore, may have simply been a result of
the difficult fragmentation of argenine residues.
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Figure 4.8

MS/MS spectrum of GRGDSPS peptide standard; a denotes fragments calculated by complementarity.
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Figure 4.9

MS/MS spectrum of GRGDSPS peptide post sorting; a denotes fragments calculated by complementarity.
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Fragment
b1
b2
b3
b4
b5
b6 - amine
y1
y2
y3
y4
y5
y6 - amine

Expected
58.03
214.13
271.15
386.18
473.21
553.23
105.06
202.12
289.15
404.18
461.20
600.27

Found
58.11a
214.12
271.14
386.17
473.19
553.19
105.12a
202.12
289.15
404.17
461.21a
600.23

Residue Lost
Arg
Gly
Asp
Ser
Pro
Ser
Pro
Ser
Asp
Gly
Arg
Gly

Table 4.3 Calculated and observed fragmentation patterns for untreated GRGDSPS
peptide. a Fragments were calculated by complementarity.

Fragment
b1
b2
b3
b4
b5
b6 - amine
y1
y2
y3
y4
y5 - amine
y6

Table 4.4

Expected
58.05
214.15
271.17
386.20
473.23
553.25
105.08
202.14
289.17
404.20
445.20
617.32

Found
58.05a
214.13
271.14
386.15
473.17
553.2
105.12a
202.11
289.14
404.17
445.15
617.30

Residue Lost
Arg
Gly
Asp
Ser
Pro
Ser
Pro
Ser
Asp
Gly
Arg
Gly

Calculated and observed fragmentation patterns for GRGDSPS peptide post
sorting. a Fragments were calculated by complementarity.
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Fragment
b1

Expected
58.05

Found
58.08a

Residue
Arg

b2
c3

214.15
289.20

214.13
289.16

Gly
Asp

b4
b5 - amine
c6
y1
y2
y3
y4
y5

386.19
456.20
654.33
119.10
282.16
369.19
484.22
573.27

386.17
456.16
654.24
118.16a
282.15
369.15
483.22a
573.22

Ser
Tyr
Thr
Tyr
Ser
Asp
Gly
Arg

z6

680.33

680.26

Gly

Fragment
b1
b2
b3
b4
b5
b6
y1
y2
y3
y4
z5
y6

Expected
58.09

Found
N/A

Residue
-

214.19
271.21
386.23
473.27
636.33
119.14
282.20
369.23
484.26
558.30
697.38

214.13
271.15
386.16
473.21
636.71
119.09
282.16
369.14
484.26a
559.17
N/A

Gly
Asp
Ser
Tyr
Thr
Tyr
Ser
Asp
Gly
Arg
-

Table 4.5 Experimental and calculated fragmentation of untreated (left) and sorted
(right) H-GRGDSYT-NH2 peptide (2).

a

Fragments were calculated by

complementarity.

Fragment

Expected

Found

Residue

Expected

Found

Residue

b1

58.03

N/A

-

b1

58.03

N/A

-

b2

214.13

214.12

Gly

b2

214.13

214.12

Gly

b3

271.15

271.15

Asp

b3

271.15

271.15

Asp

b4

386.18

386.16

Ser

b4

386.18

386.16

Ser

b5

473.21

473.19

Trp

b5

473.21

473.17

Trp

b6

659.29

659.24

Lys

b6

659.29

659.74

Lys

z1

129.10

129.10

Trp

z1

129.10

129.10

Trp

z2

315.18

315.19

Ser

z2

315.18

315.15

Ser

402.21

402.23

a

Asp

a

Gly

y3
z4
y5
z6

419.23

419.22

517.24

517.24

a

Gly

z4

517.24

517.24

589.28

a

Arg

y5

589.28

589.17

Arg

-

z6

746.38

N/A

-

589.28
746.38

N/A

Asp

Fragment

z3

Table 4.6 Experimental and calculated fragmentation of untreated (left) and sorted
(right) H-GRGDSWK-NH2 peptide (3).
complementarity.

a

Fragments were calculated by
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Fragment

Expected
58.05

Found
58.03a

Residue
Arg

b2

214.15

214.08

Gly

Asp

b3

271.17

270.39

Asp

Ser

b4

386.20

386.17

Ser

473.19

His

b5

473.23

473.18

His

610.21

Leu

b6

610.29

610.21

Leu

131.08

130.16a

Leu

y1

131.11

130.19a

Leu

268.14

268.18

His

y2

268.17

268.15

His

355.20

355.20

Asp

Expected

Found

Residue

b1

58.02

N/A

-

b2

214.12

214.13

Gly

b3

271.14

271.16

a

b4

386.17

386.16

b5

473.20

b6

610.26

y1
y2

Fragment
b1

y3

355.17

355.20

Asp

y3

y4

470.23

470.22

Gly

y4

470.26

470.01a

Gly

527.28

527.21

Arg

683.38

682.37

Gly

y5

527.25

527.22

Arg

y5

y6

683.35

N/A

-

y6

Table 4.7 Experimental and calculated fragmentation of untreated (left) and sorted
(right) H-GRGDSHL-NH2 peptide (4).

a

Fragments were calculated by

complementarity.

Fragment
b1

Expected

Found

Residue

Expected

Found

Residue

58.01

58.08a

Arg

b1

58.04

58.08a

Arg

a

Gly

b2

214.14

214.13

Gly

Fragment

b2

214.11

214.14

b3

271.13

271.16

Asp

b3

271.17

271.16

Asp

b4

386.16

386.16

Ser

b4

386.19

386.16

Ser

b5

473.19

473.19

Val

b5

473.22

473.17

Val

b6

572.26

572.24

Pro

b6

572.29

572.21

Pro

y1

115.07

115.08

Pro

y1

115.10

115.08

Pro

214.17

214.14

a

Val

a

Asp

y2

214.14

214.14

Val

y2

y3 - amine

284.14

284.13

Asp

y3 - amine

284.17

283.18

y4 - amine

399.18

399.16

Gly

y4 - amine

399.21

399.15

Gly

y5 - amine

456.20

456.16

Arg

y5 - amine

456.23

456.17

Arg

y6 - amine

612.29

612.24

Gly

y6 - amine

612.32

612.77

Gly

Table 4.8 Experimental and calculated fragmentation of untreated (left) and sorted
(right) H-GRGDSVP-NH2 peptide (5).
complementarity.

a

Fragments were calculated by
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Fragment

Expected

Found

Residue

Fragment

Expected

Found

Residue

b1

58.04

N/A

-

b1

58.05

N/A

-

b2

214.14

214.12

Gly

b2

214.15

214.12

Gly

b3

271.16

271.15

Asp

b3

271.17

271.19

Asp

b4

386.19

386.17

Ser

b4

386.20

386.16

Ser

473.23

473.18

Thr

b5

473.22

473.2

Thr

b5

b6

573.26

573.22

Trp

b6

573.27

573.23

Trp

Thr

y1

204.10

204.12

Thr

y1

204.09

204.11

y2

305.14

305.15

Ser

y2

305.15

305.14

Ser

z3

407.18

407.14

Asp

z3

407.19

407.14

Asp

y4 - amine

491.18

491.20

Gly

y4 - amine

491.19

491.19

Gly

564.22

a

Arg

y5

564.23

564.28

Arg

-

y6

720.33

N/A

-

y5
y6

720.32

564.27
N/A

Table 4.9 Experimental and calculated fragmentation of untreated (left) and sorted
(right) H-GRGDSTW-NH2 peptide (6).

a

Fragments were calculated by

complementarity.

Fragment

Expected

Found

Residue

Expected

Found

Residue

b1

58.03

58.05a

Arg

b1

58.07

N/A

-

b2

214.13

214.13

Gly

b2

214.17

214.13

Gly

b3

271.15

271.15

Asp

c3

289.23

289.14

Asp

b4

386.18

386.17

Ser

b4

386.22

386.16

Ser

b5

473.21

473.20

Phe

b5 - amine

456.22

456.17

Phe

b6

619.27

619.36

Ala

b6

619.31

620.26

Ala

a

Phe

a

Fragment

y1

89.07

89.00

Phe

y1

89.11

89.13

y2

236.14

236.12

Ser

y2

236.18

235.12

Ser

y3

323.17

323.16

Asp

y3

323.21

323.14

Asp

y4

438.20

438.16

Gly

y4

438.24

438.28a

Gly

y5

495.22

496.24

Arg

y5

495.26

495.26

Arg

z6

634.29

634.27

Gly

y6 - amine

634.33

N/A

-

Table 4.10 Experimental and calculated fragmentation of untreated (left) and sorted
(right) H-GRGDSFA-NH2 peptide (7). a Fragments were calculated by
complementarity.
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Scheme 4.2

Possible fragmentation patterns of the Arginine side chain.

Considering that cells were still bound to peptide-conjugated Tentagel beads after
sorting, attempts were made to facilitate cell removal via sequential heating at 60 oC and
95 oC over 10 min and 15 min, respectively. Unfortunately, this methodology prevented
proper fragmentation of peptide sequences by MALDI-TOF/TOF to such an extent that
no fragmentation was observed for peptides 3, 5, 6, and 7, while partial fragmentations
were observed for other peptides. This could have been resulted from peptide
decomposition or release from Tentagel beads. Although attempts to facilitate cell
removal were not successful, complete sequencing of library peptides, without cell
removal via sequential heating, proves this process to be unnecessary.
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4.4

Conclusions
A novel and rapid cell-based, on-bead, and fully automated screening process for

one-bead one-compound libraries was developed. As proof of concept, a small library of
heptameric peptides expressing the GRGDS moiety, known to bind αvβ3 integrins, was
synthesized on Tentagel beads. The peptide-conjugated beads were screened against αvβ3
expressing MDA-MB-435 cell-line, which were transfected with GFP protein. Cells were
fixed to beads via formaldehyde treatment. Automated isolation of hit beads was
accomplished using a COPAS large particle flow cytometer. MALDI-TOF/TOF analysis
and successful sequencing of all prepared peptides indicated efficient screening and
isolation of hit beads by the COPAS flow cytometer. An attempt was made to facilitate
removal of cells from beads after sorting. However, this resulted in peptide
degradation/release from Tentagel beads. This process, however, was deemed
unnecessary since peptide sequences were deconvoluted successfully without removing
cells from the Tentagel beads.
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CHAPTER 5. Outlook and Concluding Remarks

The research discussed in this dissertation provides new possibilities and insights
into the preparation of nuclear (PET/SPECT) and fluorescent (fluorescence microscopy)
imaging probes, entailing several important findings which should be considered in the
basic design of a tracer, especially when working with peptides or multiple imaging
modalities. These findings include: 1) charge distribution on the peptide backbone
contributes to probe clearance and uptake pathways, 2) by using porphyrin derivatives, a
single molecule tracer can be developed for multimodality imaging, without requiring the
use of multiple imaging tags or structural modifications, and 3) screening of OBOC
libraries can be facilitated by using a fluorescent-based cell sorter, after fixing cells to
beads, and utilized immediately after library preparation. Here, the significance of these
findings and their contribution to the field of molecular/diagnostic imaging is discussed in
more detail.
The first important finding was discovered in the development of peptide-based
tracers for beta cell imaging. Nine GLP-1 analogues were initially prepared and evaluated
in vitro. Among these, several promising candidates were identified, the most promising
of which was used for in vivo evaluation. Although pancreatic uptake was confirmed exvivo, non-specific uptake of the tracer in kidneys prevented direct visualization of islets.
Following these observations, the imaging probe was structurally modified in order to
reduce kidney retention. Results obtained in this research suggested that the localization
and clearance of peptide-based probes could be significantly altered based on the charge
localization on the peptide backbone. This is an important observation as the non-specific
uptake of tracers often interfere with proper in vivo evaluation of targeting agents. This
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interference, as suggested by results in this dissertation, could be circumvented by
perturbation of charge distribution in peptide-based agents, thereby improving images
obtained in in vivo studies. This is especially noteworthy in the development of tracers
targeting GLP-1R, considering the intended biological disease (diabetes), and the
potential contribution towards the development of a cure.
Until now, there have been no reports on an imaging probe that could be used for
the non-invasive and direct visualization of pancreatic islets in vivo. The development of
a probe for this application would allow not only the visualization but also the
quantification of beta cell mass during the onset of diabetes type 1 and its progression
into diabetes type 2. This would serve as a more efficient route of monitoring disease
progression while, perhaps, providing the experts with a better method of analysis for
beta cell transfer operations, thereby providing better options for the treatment of this
illness.1 Visualization of beta cell mass could also prove to be a valuable diagnostic tool
for monitoring of other disease processes involving GLP-1R receptors, such as pancreatic
cancers (e.g. insulinomas). While the optimization process is currently ongoing, the work
discussed in this dissertation provides potential imaging probe candidates that could be
used for the above application.
The second finding concerns the basic design of multimodality imaging
probes. In recent years, utilization of multiple imaging modalities has gained significant
popularity since it provides more information on targeted biological entities. This move
towards multimodality imaging requires the development of appropriate tracers for use
with the intended instrumentation. A progression in this field was observed with the
development of multimodality single molecule probes. However, such compounds were

191
commonly prepared by attachment of multiple imaging tags, which altered the innate
properties of the parent molecule. This also resulted in unexpected and in consistent in
vivo properties, in between modalities. The use of a single molecule for multimodality
imaging, without structural modifications or addition of multiple imaging tags, is the next
step in the development of more efficient imaging probes. A recent report by Valliant and
coworkers provided an example of this concept.2 The work in this dissertation puts forth
a new route for the development of such probes using porphyrins for both fluorescence
and radiometal chelation. In confirming this ideology, gallium-chelated porphyrins,
containing the integrin-targeting moiety RGD, were developed. Surprisingly, optical
analysis of the prepared compounds indicated metal-dependent fluorescence-quenching
to be minimal. This is contrary to reported literature on the negative impacts of metal
chelation (Mg, Sn, Zn) on fluorescence quantum yields of PPIX.3 Furthermore, in vitro
analysis proved the potential of the developed tracers for fluorescence microscopy, while
radiolabeling experiments confirmed the potential for PET imaging. This methodology
could prove to be particularly beneficial in bridging the gap between the screening
processes requiring initial in vitro evaluation, by means of fluorescence microscopy, and
in vivo detection via nuclear imaging, with implications in the development of novel
probes, drugs and therapeutics.
This work also provides a more efficient and facile route for screening peptide
libraries. Although a number of screening methods have already been reported in
literature,4-6 there are currently no reports on a cell-based procedure which can be used
with OBOC peptide libraries without the need for structural modification. As a result this
procedure simplifies the screening process by providing users with the ability to evaluate
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novel peptide sequences, immediately after synthesis, in a time and cost-efficient fashion.
While this method was validated with a small peptide library, its application can
potentially be extended to also include other compounds such as small molecules or
proteins.
In overview, this dissertation provides new routes for the synthesis and
screening of peptide-based agents with applications in diagnostic imaging and potentially
oncology. In addition, this research not only offers new insight into pharmacokinetic
control with structural modifications, but also presents novel synthetic routes for
preparation of more reliable and efficient multimodality imaging agents. The results
described herein will contribute to the discovery of targeting ligands in basic sciences and
ultimately to the discovery of new drugs and therapeutics.
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APPENDIX I - CHAPTER 2
HPLC and MS-ESI spectra of 1 (Purity 90%)

Solvent
Peak

195
HPLC and MS-ESI spectra of 2 (Purity 98%)
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HPLC and MS-ESI spectra of 3 (Purity 95%)
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HPLC and MS-ESI spectra of 4 (Purity 90%)
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HPLC and MS-ESI spectra of 5 (85.3%)
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Dr. L. Luyt, B. Azad, 34-IN-D-GLP
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HPLC and MS-ESI spectra of 6 (Purity 97%)
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Dr. L. Luyt, B. Azad, 34-A-I-D-GLP
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HPLC and MS-ESI spectra of 7 (Purity 98%)
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HPLC and MS-ESI spectra of 8 (Purity 95.3%)
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APPENDIX II – CHAPTER 3
UV and ESI-MS Spectra of HPLC-Purified 2
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UV and ESI-MS Spectra of HPLC-Purified 3
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UV and ESI-MS Spectra of HPLC-Purified 4
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UV and ESI-MS Spectra of HPLC-Purified 5
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UV and ESI-MS Spectra of HPLC-Purified 6
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UV and ESI-MS Spectra of HPLC-Purified 7
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UV and ESI-MS Spectra of HPLC-Purified 8
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UV and ESI-MS Spectra of HPLC-Purified 9
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MS/MS spectrum of untreated H-GRGDSYT-NH2 (2) post cleavage from tentagel resin
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MS/MS spectrum of sorted H-GRGDSYT-NH2 (2) after cleavage from tentagel resin
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MS/MS spectrum of untreated H-GRGDSWK-NH2 (3) after cleavage from tentagel resin
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MS/MS spectrum of sorted H-GRGDSWK-NH2 (3) after cleavage from tentagel resin
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MS/MS spectrum of untreated H-GRGDSHL-NH2 (4) after cleavage from tentagel resin
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MS/MS spectrum of sorted H-GRGDSHL-NH2 (4) after cleavage from tentagel resin
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MS/MS spectrum of untreated H-GRGDSVP-NH2 (5) after cleavage from tentagel resin
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MS/MS spectrum of sorted H-GRGDSVP-NH2 (5) after cleavage from tentagel resin
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MS/MS spectrum of untreated H-GRGDSTW-NH2 (6) after cleavage from tentagel resin

219

MS/MS spectrum of sorted H-GRGDSTW-NH2 (6) after cleavage from tentagel resin
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MS/MS spectrum of untreated H-GRGDSFA-NH2 (7) after cleavage from tentagel resin

221

MS/MS spectrum of sorted H-GRGDSFA-NH2 (7) after cleavage from tentagel resin
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